



US010159842B2

(12) **United States Patent**
Kane et al.

(10) **Patent No.:** **US 10,159,842 B2**
(45) **Date of Patent:** **Dec. 25, 2018**

(54) **SYSTEM AND METHOD FOR DETECTING
TAMPONADE**

(71) Applicant: **Cardiac Pacemakers, Inc.**, St. Paul,
MN (US)

(72) Inventors: **Michael J. Kane**, Roseville, MN (US);
Allan Charles Shuros, St. Paul, MN
(US); **Brian L. Schmidt**, White Bear
Lake, MN (US); **Keith R. Maile**, New
Brighton, MN (US); **Benjamin J.
Haasl**, Forest Lake, MN (US)

(73) Assignee: **Cardiac Pacemakers, Inc.**, St. Paul,
MN (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 56 days.

(21) Appl. No.: **15/244,571**

(22) Filed: **Aug. 23, 2016**

(65) **Prior Publication Data**

US 2017/0056671 A1 Mar. 2, 2017

Related U.S. Application Data

(60) Provisional application No. 62/211,333, filed on Aug.
28, 2015.

(51) **Int. Cl.**
A61N 1/37 (2006.01)
A61B 5/02 (2006.01)

(Continued)

(52) **U.S. Cl.**
CPC **A61N 1/3704** (2013.01); **A61B 5/0031**
(2013.01); **A61B 5/024** (2013.01);
(Continued)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,835,864 A 9/1974 Rasor et al.
3,943,936 A 3/1976 Rasor et al.

(Continued)

FOREIGN PATENT DOCUMENTS

AU 2008279789 B2 10/2011
AU 2008329620 B2 5/2014

(Continued)

OTHER PUBLICATIONS

US 8,886,318, 11/2014, Jacobson et al. (withdrawn)

(Continued)


Primary Examiner — Erica Lee

(74) *Attorney, Agent, or Firm* — Seager, Tufte &
Wickhem LLP

(57) **ABSTRACT**

Systems, methods, and devices for determining occurrences of a tamponade condition are disclosed. One exemplary method includes monitoring an accelerometer signal of a leadless cardiac pacemaker attached to a heart wall, determining if a tamponade condition of the patient's heart is indicated based at least in part on the monitored accelerometer signal, and in response to determining that the tamponade condition is indicated, providing a notification of the tamponade condition for use by a physician to take corrective action.

18 Claims, 9 Drawing Sheets



- (51) **Int. Cl.**
A61B 5/024 (2006.01)
A61B 5/00 (2006.01)
A61N 1/05 (2006.01)
A61N 1/375 (2006.01)
A61B 5/029 (2006.01)
A61B 5/11 (2006.01)
- (52) **U.S. Cl.**
 CPC *A61B 5/029* (2013.01); *A61B 5/02028* (2013.01); *A61B 5/11* (2013.01); *A61B 5/6869* (2013.01); *A61N 1/057* (2013.01); *A61N 1/3756* (2013.01); *A61B 2562/0219* (2013.01)
- (56) **References Cited**
 U.S. PATENT DOCUMENTS
- | | | | | | |
|-------------|---------|---------------------|-------------|---------|-------------------|
| 4,142,530 A | 3/1979 | Wittkampf | 5,300,107 A | 4/1994 | Stokes et al. |
| 4,151,513 A | 4/1979 | Menken et al. | 5,301,677 A | 4/1994 | Hsung |
| 4,157,720 A | 6/1979 | Greatbatch | 5,305,760 A | 4/1994 | McKown et al. |
| RE30,366 E | 8/1980 | Rasor et al. | 5,312,439 A | 5/1994 | Loeb |
| 4,243,045 A | 1/1981 | Maas | 5,313,953 A | 5/1994 | Yomtov et al. |
| 4,250,884 A | 2/1981 | Hartlaub et al. | 5,314,459 A | 5/1994 | Swanson et al. |
| 4,256,115 A | 3/1981 | Bilitch | 5,318,597 A | 6/1994 | Hauck et al. |
| 4,263,919 A | 4/1981 | Levin | 5,324,316 A | 6/1994 | Schulman et al. |
| 4,310,000 A | 1/1982 | Lindemans | 5,331,966 A | 7/1994 | Bennett et al. |
| 4,312,354 A | 1/1982 | Walters | 5,334,222 A | 8/1994 | Salo et al. |
| 4,323,081 A | 4/1982 | Wiebusch | 5,342,408 A | 8/1994 | Decoriolis et al. |
| 4,357,946 A | 11/1982 | Dutcher et al. | 5,370,667 A | 12/1994 | Alt |
| 4,365,639 A | 12/1982 | Goldreyer | 5,372,606 A | 12/1994 | Lang et al. |
| 4,440,173 A | 4/1984 | Hudziak et al. | 5,376,106 A | 12/1994 | Stahmann et al. |
| 4,476,868 A | 10/1984 | Thompson | 5,383,915 A | 1/1995 | Adams |
| 4,522,208 A | 6/1985 | Buffet | 5,388,578 A | 2/1995 | Yomtov et al. |
| 4,537,200 A | 8/1985 | Widrow | 5,404,877 A | 4/1995 | Nolan et al. |
| 4,556,063 A | 12/1985 | Thompson et al. | 5,405,367 A | 4/1995 | Schulman et al. |
| 4,562,841 A | 1/1986 | Brockway et al. | 5,411,031 A | 5/1995 | Yomtov |
| 4,593,702 A | 6/1986 | Kepski et al. | 5,411,525 A | 5/1995 | Swanson et al. |
| 4,593,955 A | 6/1986 | Leiber | 5,411,535 A | 5/1995 | Fujii et al. |
| 4,630,611 A | 12/1986 | King | 5,456,691 A | 10/1995 | Snell |
| 4,635,639 A | 1/1987 | Hakala et al. | 5,458,622 A | 10/1995 | Alt |
| 4,674,508 A | 6/1987 | DeCote | 5,466,246 A | 11/1995 | Silvian |
| 4,712,554 A | 12/1987 | Garson | 5,468,254 A | 11/1995 | Hahn et al. |
| 4,729,376 A | 3/1988 | DeCote | 5,472,453 A | 12/1995 | Alt |
| 4,754,753 A | 7/1988 | King | 5,480,412 A | 1/1996 | Mouchawar et al. |
| 4,759,366 A | 7/1988 | Callaghan | 5,496,361 A | 3/1996 | Moberg et al. |
| 4,776,338 A | 10/1988 | Lekholm et al. | 5,522,866 A | 6/1996 | Fernald |
| 4,787,389 A | 11/1988 | Tarjan | 5,540,727 A | 7/1996 | Tockman et al. |
| 4,793,353 A | 12/1988 | Borkan | 5,545,186 A | 8/1996 | Olson et al. |
| 4,819,662 A | 4/1989 | Heil et al. | 5,545,202 A | 8/1996 | Dahl et al. |
| 4,858,610 A | 8/1989 | Callaghan et al. | 5,549,652 A | 8/1996 | McClure et al. |
| 4,886,064 A | 12/1989 | Strandberg | 5,571,146 A | 11/1996 | Jones et al. |
| 4,887,609 A | 12/1989 | Cole, Jr. | 5,591,214 A | 1/1997 | Lu |
| 4,928,688 A | 5/1990 | Mower | 5,620,466 A | 4/1997 | Haefner et al. |
| 4,967,746 A | 11/1990 | Vandegriff | 5,634,938 A | 6/1997 | Swanson et al. |
| 4,987,897 A | 1/1991 | Funke | 5,649,968 A | 7/1997 | Alt et al. |
| 4,989,602 A | 2/1991 | Sholder et al. | 5,662,688 A | 9/1997 | Haefner et al. |
| 5,012,806 A | 5/1991 | De Bellis | 5,674,259 A | 10/1997 | Gray |
| 5,036,849 A | 8/1991 | Hauck et al. | 5,683,426 A | 11/1997 | Greenhut et al. |
| 5,040,534 A | 8/1991 | Mann et al. | 5,683,432 A | 11/1997 | Goedeke et al. |
| 5,058,581 A | 10/1991 | Silvian | 5,706,823 A | 1/1998 | Wodlinger |
| 5,078,134 A | 1/1992 | Heilman et al. | 5,709,215 A | 1/1998 | Perttu et al. |
| 5,109,845 A | 5/1992 | Yuuchi et al. | 5,720,770 A | 2/1998 | Nappholz et al. |
| 5,113,859 A | 5/1992 | Funke | 5,728,154 A | 3/1998 | Crossett et al. |
| 5,117,824 A | 6/1992 | Keimel et al. | 5,741,314 A | 4/1998 | Daly et al. |
| 5,127,401 A | 7/1992 | Grevious et al. | 5,741,315 A | 4/1998 | Lee et al. |
| 5,133,353 A | 7/1992 | Hauser | 5,752,976 A | 5/1998 | Duffin et al. |
| 5,144,950 A | 9/1992 | Stoop et al. | 5,752,977 A | 5/1998 | Grevious et al. |
| 5,170,784 A | 12/1992 | Ramon et al. | 5,755,736 A | 5/1998 | Gillberg et al. |
| 5,179,945 A | 1/1993 | Van Hofwegen et al. | 5,759,199 A | 6/1998 | Snell et al. |
| 5,193,539 A | 3/1993 | Schulman et al. | 5,774,501 A | 6/1998 | Halpern et al. |
| 5,193,540 A | 3/1993 | Schulman et al. | 5,792,195 A | 8/1998 | Carlson et al. |
| 5,241,961 A | 9/1993 | Henry | 5,792,202 A | 8/1998 | Rueter |
| 5,243,977 A | 9/1993 | Trabucco et al. | 5,792,203 A | 8/1998 | Schroepel |
| 5,259,387 A | 11/1993 | dePinto | 5,792,205 A | 8/1998 | Alt et al. |
| 5,269,326 A | 12/1993 | Verrier | 5,792,208 A | 8/1998 | Gray |
| 5,284,136 A | 2/1994 | Hauck et al. | 5,814,089 A | 9/1998 | Stokes et al. |
| | | | 5,827,216 A | 10/1998 | Igo et al. |
| | | | 5,836,985 A | 11/1998 | Goyal et al. |
| | | | 5,836,987 A | 11/1998 | Baumann et al. |
| | | | 5,842,977 A | 12/1998 | Lesho et al. |
| | | | 5,855,593 A | 1/1999 | Olson et al. |
| | | | 5,873,894 A | 2/1999 | Vandegriff et al. |
| | | | 5,891,184 A | 4/1999 | Lee et al. |
| | | | 5,897,586 A | 4/1999 | Molina |
| | | | 5,899,876 A | 5/1999 | Flower |
| | | | 5,899,928 A | 5/1999 | Sholder et al. |
| | | | 5,919,214 A | 7/1999 | Ciciarelli et al. |
| | | | 5,935,078 A | 8/1999 | Feierbach |
| | | | 5,941,906 A | 8/1999 | Barreras et al. |
| | | | 5,944,744 A | 8/1999 | Paul et al. |
| | | | 5,954,757 A | 9/1999 | Gray |
| | | | 5,978,713 A | 11/1999 | Prutchi et al. |
| | | | 5,991,660 A | 11/1999 | Goyal |
| | | | 5,991,661 A | 11/1999 | Park et al. |
| | | | 5,999,848 A | 12/1999 | Gord et al. |
| | | | 5,999,857 A | 12/1999 | Weijand et al. |

(56)

References Cited

U.S. PATENT DOCUMENTS

6,002,963	A	12/1999	Mouchawar	6,470,215	B1	10/2002	Kraus et al.
6,016,445	A	1/2000	Baura	6,471,645	B1	10/2002	Warkentin et al.
6,026,320	A	2/2000	Carlson et al.	6,480,745	B2	11/2002	Nelson et al.
6,029,085	A	2/2000	Olson et al.	6,487,443	B2	11/2002	Olson et al.
6,041,250	A	3/2000	dePinto	6,490,487	B1	12/2002	Kraus et al.
6,044,298	A	3/2000	Salo et al.	6,498,951	B1	12/2002	Larson et al.
6,044,300	A	3/2000	Gray	6,507,755	B1	1/2003	Gozani et al.
6,055,454	A	4/2000	Heemels	6,507,759	B1	1/2003	Prutchi et al.
6,073,050	A	6/2000	Griffith	6,512,940	B1	1/2003	Brabec et al.
6,076,016	A	6/2000	Feierbach	6,522,915	B1	2/2003	Ceballos et al.
6,077,236	A	6/2000	Cunningham	6,526,311	B2	2/2003	Begemann
6,080,187	A	6/2000	Alt et al.	6,539,253	B2	3/2003	Thompson et al.
6,083,248	A	7/2000	Thompson	6,542,775	B2	4/2003	Ding et al.
6,106,551	A	8/2000	Crossett et al.	6,553,258	B2	4/2003	Stahmann et al.
6,115,636	A	9/2000	Ryan	6,561,975	B1	5/2003	Pool et al.
6,128,526	A	10/2000	Stadler et al.	6,564,807	B1	5/2003	Schulman et al.
6,141,581	A	10/2000	Olson et al.	6,574,506	B2	6/2003	Kramer et al.
6,141,588	A	10/2000	Cox et al.	6,584,351	B1	6/2003	Ekwall
6,141,592	A	10/2000	Pauly	6,584,352	B2	6/2003	Combs et al.
6,144,879	A	11/2000	Gray	6,597,948	B1	7/2003	Rockwell et al.
6,162,195	A	12/2000	Igo et al.	6,597,951	B2	7/2003	Kramer et al.
6,164,284	A	12/2000	Schulman et al.	6,622,046	B2	9/2003	Fraley et al.
6,167,310	A	12/2000	Grevious	6,628,985	B2	9/2003	Sweeney et al.
6,201,993	B1	3/2001	Kruse et al.	6,647,292	B1	11/2003	Bardy et al.
6,208,894	B1	3/2001	Schulman et al.	6,666,844	B1	12/2003	Igo et al.
6,211,799	B1	4/2001	Post et al.	6,689,117	B2	2/2004	Sweeney et al.
6,221,011	B1	4/2001	Bardy	6,690,959	B2	2/2004	Thompson
6,240,316	B1	5/2001	Richmond et al.	6,694,189	B2	2/2004	Begemann
6,240,317	B1	5/2001	Villaseca et al.	6,704,602	B2	3/2004	Berg et al.
6,256,534	B1	7/2001	Dahl	6,718,212	B2	4/2004	Parry et al.
6,259,947	B1	7/2001	Olson et al.	6,721,597	B1	4/2004	Bardy et al.
6,266,558	B1	7/2001	Gozani et al.	6,738,670	B1	5/2004	Almendinger et al.
6,266,567	B1	7/2001	Ishikawa et al.	6,746,797	B2	6/2004	Benson et al.
6,270,457	B1	8/2001	Bardy	6,749,566	B2	6/2004	Russ
6,272,377	B1	8/2001	Sweeney et al.	6,758,810	B2	7/2004	Lebel et al.
6,273,856	B1	8/2001	Sun et al.	6,763,269	B2	7/2004	Cox
6,277,072	B1	8/2001	Bardy	6,778,860	B2	8/2004	Ostroff et al.
6,280,380	B1	8/2001	Bardy	6,788,971	B1	9/2004	Sloman et al.
6,285,907	B1	9/2001	Kramer et al.	6,788,974	B2	9/2004	Bardy et al.
6,292,698	B1	9/2001	Duffin et al.	6,804,558	B2	10/2004	Haller et al.
6,295,473	B1	9/2001	Rosar	6,807,442	B1	10/2004	Myklebust et al.
6,297,943	B1	10/2001	Carson	6,847,844	B2	1/2005	Sun et al.
6,298,267	B1	10/2001	Rosborough et al.	6,871,095	B2	3/2005	Stahmann et al.
6,298,271	B1	10/2001	Weijand	6,878,112	B2	4/2005	Linberg et al.
6,307,751	B1	10/2001	Bodony et al.	6,885,889	B2	4/2005	Chinchoy
6,312,378	B1	11/2001	Bardy	6,892,094	B2	5/2005	Ousdigian et al.
6,315,721	B2	11/2001	Schulman et al.	6,897,788	B2	5/2005	Khair et al.
6,336,903	B1	1/2002	Bardy	6,904,315	B2	6/2005	Panken et al.
6,345,202	B2	2/2002	Richmond et al.	6,922,592	B2	7/2005	Thompson et al.
6,351,667	B1	2/2002	Godie	6,931,282	B2	8/2005	Esler
6,351,669	B1	2/2002	Hartley et al.	6,934,585	B1	8/2005	Schloss et al.
6,353,759	B1	3/2002	Hartley et al.	6,957,107	B2	10/2005	Rogers et al.
6,358,203	B2	3/2002	Bardy	6,978,176	B2	12/2005	Lattouf
6,361,780	B1	3/2002	Ley et al.	6,985,773	B2	1/2006	Von Arx et al.
6,368,284	B1	4/2002	Bardy	6,990,375	B2	1/2006	Kloss et al.
6,371,922	B1	4/2002	Baumann et al.	7,001,366	B2	2/2006	Ballard
6,398,728	B1	6/2002	Bardy	7,003,350	B2	2/2006	Denker et al.
6,400,982	B2	6/2002	Sweeney et al.	7,006,864	B2	2/2006	Echt et al.
6,400,990	B1	6/2002	Silvian	7,013,178	B2	3/2006	Reinke et al.
6,408,208	B1	6/2002	Sun	7,027,871	B2	4/2006	Burnes et al.
6,409,674	B1	6/2002	Brockway et al.	7,050,849	B2	5/2006	Echt et al.
6,411,848	B2	6/2002	Kramer et al.	7,060,031	B2	6/2006	Webb et al.
6,424,865	B1	7/2002	Ding	7,063,693	B2	6/2006	Guenst
6,434,429	B1	8/2002	Kraus et al.	7,082,336	B2	7/2006	Ransbury et al.
6,438,410	B2	8/2002	Hsu et al.	7,085,606	B2	8/2006	Flach et al.
6,438,417	B1	8/2002	Rockwell et al.	7,092,758	B2	8/2006	Sun et al.
6,438,421	B1	8/2002	Stahmann et al.	7,110,824	B2	9/2006	Amundson et al.
6,440,066	B1	8/2002	Bardy	7,120,504	B2	10/2006	Osyypka
6,441,747	B1	8/2002	Khair et al.	7,130,681	B2	10/2006	Gebhardt et al.
6,442,426	B1	8/2002	Kroll	7,139,613	B2	11/2006	Reinke et al.
6,442,432	B2	8/2002	Lee	7,142,912	B2	11/2006	Wagner et al.
6,443,891	B1	9/2002	Grevious	7,146,225	B2	12/2006	Guenst et al.
6,445,953	B1	9/2002	Bulkes et al.	7,146,226	B2	12/2006	Lau et al.
6,453,200	B1	9/2002	Koslar	7,149,581	B2	12/2006	Goedeke
6,459,929	B1	10/2002	Hopper et al.	7,149,588	B2	12/2006	Lau et al.
				7,158,839	B2	1/2007	Lau
				7,162,307	B2	1/2007	Patrias
				7,164,952	B2	1/2007	Lau et al.
				7,177,700	B1	2/2007	Cox

(56)

References Cited

U.S. PATENT DOCUMENTS

7,181,505	B2	2/2007	Haller et al.	7,668,596	B2	2/2010	Von Arx et al.
7,184,830	B2	2/2007	Echt et al.	7,682,316	B2	3/2010	Anderson et al.
7,186,214	B2	3/2007	Ness	7,691,047	B2	4/2010	Ferrari
7,191,015	B2	3/2007	Lamson et al.	7,702,392	B2	4/2010	Echt et al.
7,200,437	B1	4/2007	Nabutovsky et al.	7,713,194	B2	5/2010	Zdeblick
7,200,439	B2	4/2007	Zdeblick et al.	7,713,195	B2	5/2010	Zdeblick
7,206,423	B1	4/2007	Feng et al.	7,729,783	B2	6/2010	Michels et al.
7,209,785	B2	4/2007	Kim et al.	7,734,333	B2	6/2010	Ghanem et al.
7,209,790	B2	4/2007	Thompson et al.	7,734,343	B2	6/2010	Ransbury et al.
7,211,884	B1	5/2007	Davis et al.	7,738,958	B2	6/2010	Zdeblick et al.
7,212,871	B1	5/2007	Morgan	7,738,964	B2	6/2010	Von Arx et al.
7,226,440	B2	6/2007	Gelfand et al.	7,742,812	B2	6/2010	Ghanem et al.
7,228,183	B2	6/2007	Sun et al.	7,742,816	B2	6/2010	Masoud et al.
7,236,821	B2	6/2007	Cates et al.	7,742,822	B2	6/2010	Masoud et al.
7,236,829	B1	6/2007	Farazi et al.	7,743,151	B2	6/2010	Vallapureddy et al.
7,254,448	B2	8/2007	Almendinger et al.	7,747,335	B2	6/2010	Williams
7,260,436	B2	8/2007	Kilgore et al.	7,751,881	B2	7/2010	Cowan et al.
7,267,649	B2	9/2007	Zdeblick et al.	7,758,521	B2	7/2010	Morris et al.
7,270,669	B1	9/2007	Sra	7,761,150	B2	7/2010	Ghanem et al.
7,272,448	B1	9/2007	Morgan et al.	7,761,164	B2	7/2010	Verhoef et al.
7,277,755	B1	10/2007	Falkenberg et al.	7,765,001	B2	7/2010	Echt et al.
7,280,872	B1	10/2007	Mosesov et al.	7,769,452	B2	8/2010	Ghanem et al.
7,288,096	B2	10/2007	Chin	7,783,362	B2	8/2010	Whitehurst et al.
7,289,847	B1	10/2007	Gill et al.	7,792,588	B2	9/2010	Harding
7,289,852	B2	10/2007	Helfinstine et al.	7,797,059	B1	9/2010	Bornzin et al.
7,289,853	B1	10/2007	Campbell et al.	7,801,596	B2	9/2010	Fischell et al.
7,289,855	B2	10/2007	Nghiem et al.	7,809,438	B2	10/2010	Echt et al.
7,302,294	B2	11/2007	Kamath et al.	7,840,281	B2	11/2010	Kveen et al.
7,305,266	B1	12/2007	Kroll	7,844,331	B2	11/2010	Li et al.
7,310,556	B2	12/2007	Bulkes	7,844,348	B2	11/2010	Swoyer et al.
7,319,905	B1	1/2008	Morgan et al.	7,846,088	B2	12/2010	Ness
7,333,853	B2	2/2008	Mazar et al.	7,848,815	B2	12/2010	Briskin et al.
7,336,994	B2	2/2008	Hettrick et al.	7,848,823	B2	12/2010	Drasler et al.
7,347,819	B2	3/2008	Lebel et al.	7,860,455	B2	12/2010	Fukumoto et al.
7,366,572	B2	4/2008	Heruth et al.	7,871,433	B2	1/2011	Lattouf
7,373,207	B2	5/2008	Lattouf	7,877,136	B1	1/2011	Moffitt et al.
7,384,403	B2	6/2008	Sherman	7,877,142	B2	1/2011	Moaddeb et al.
7,386,342	B1	6/2008	Falkenberg et al.	7,881,786	B2	2/2011	Jackson
7,392,090	B2	6/2008	Sweeney et al.	7,881,798	B2	2/2011	Miesel et al.
7,406,105	B2	7/2008	DelMain et al.	7,881,810	B1	2/2011	Chitre et al.
7,406,349	B2	7/2008	Seeberger et al.	7,890,173	B2	2/2011	Briskin et al.
7,410,497	B2	8/2008	Hastings et al.	7,890,181	B2	2/2011	Denzene et al.
7,425,200	B2	9/2008	Brockway et al.	7,890,192	B1	2/2011	Kelsch et al.
7,433,739	B1	10/2008	Salys et al.	7,894,885	B2	2/2011	Bartal et al.
7,496,409	B2	2/2009	Greenhut et al.	7,894,894	B2	2/2011	Stadler et al.
7,496,410	B2	2/2009	Heil	7,894,907	B2	2/2011	Cowan et al.
7,502,652	B2	3/2009	Gaunt et al.	7,894,910	B2	2/2011	Cowan et al.
7,512,448	B2	3/2009	Malick et al.	7,894,915	B1	2/2011	Chitre et al.
7,515,969	B2	4/2009	Tockman et al.	7,899,537	B1	3/2011	Kroll et al.
7,526,342	B2	4/2009	Chin et al.	7,899,541	B2	3/2011	Cowan et al.
7,529,589	B2	5/2009	Williams et al.	7,899,542	B2	3/2011	Cowan et al.
7,532,933	B2	5/2009	Hastings et al.	7,899,554	B2	3/2011	Williams et al.
7,536,222	B2	5/2009	Bardy et al.	7,901,360	B1	3/2011	Yang et al.
7,536,224	B2	5/2009	Ritscher et al.	7,904,170	B2	3/2011	Harding
7,539,541	B2	5/2009	Quiles et al.	7,907,993	B2	3/2011	Ghanem et al.
7,544,197	B2	6/2009	Kelsch et al.	7,920,928	B1	4/2011	Yang et al.
7,558,631	B2	7/2009	Cowan et al.	7,925,343	B1	4/2011	Min et al.
7,565,195	B1	7/2009	Kroll et al.	7,930,022	B2	4/2011	Zhang et al.
7,584,002	B2	9/2009	Burnes et al.	7,930,040	B1	4/2011	Kelsch et al.
7,590,455	B2	9/2009	Heruth et al.	7,937,135	B2	5/2011	Ghanem et al.
7,606,621	B2	10/2009	Briskin et al.	7,937,148	B2	5/2011	Jacobson
7,610,088	B2	10/2009	Chinchoy	7,937,161	B2	5/2011	Hastings et al.
7,610,092	B2	10/2009	Cowan et al.	7,941,214	B2	5/2011	Kleckner et al.
7,610,099	B2	10/2009	Almendinger et al.	7,945,333	B2	5/2011	Jacobson
7,610,104	B2	10/2009	Kaplan et al.	7,946,997	B2	5/2011	Hübinette
7,616,991	B2	11/2009	Mann et al.	7,949,404	B2	5/2011	Hill
7,617,001	B2	11/2009	Penner et al.	7,949,405	B2	5/2011	Feher
7,617,007	B2	11/2009	Williams et al.	7,953,486	B2	5/2011	Daum et al.
7,630,767	B1	12/2009	Poore et al.	7,953,493	B2	5/2011	Fowler et al.
7,634,313	B1	12/2009	Kroll et al.	7,962,202	B2	6/2011	Bhunia
7,637,867	B2	12/2009	Zdeblick	7,963,925	B1	6/2011	Schechter
7,640,060	B2	12/2009	Zdeblick	7,974,702	B1	7/2011	Fain et al.
7,647,109	B2	1/2010	Hastings et al.	7,979,136	B2	7/2011	Young et al.
7,650,186	B2	1/2010	Hastings et al.	7,983,753	B2	7/2011	Severin
7,657,311	B2	2/2010	Bardy et al.	3,010,209	A1	8/2011	Jacobson
				7,991,467	B2	8/2011	Markowitz et al.
				7,991,471	B2	8/2011	Ghanem et al.
				7,996,087	B2	8/2011	Cowan et al.
				8,000,791	B2	8/2011	Sunagawa et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

8,000,807 B2	8/2011	Morris et al.	8,369,962 B2	2/2013	Abrahamson
8,001,975 B2	8/2011	DiSilvestro et al.	8,380,320 B2	2/2013	Spital
8,002,700 B2	8/2011	Ferek-Petric et al.	8,386,051 B2	2/2013	Rys
8,019,419 B1	9/2011	Panescu et al.	8,391,981 B2	3/2013	Mosesov
8,019,434 B2	9/2011	Quiles et al.	8,391,990 B2	3/2013	Smith et al.
8,027,727 B2	9/2011	Freeberg	8,406,874 B2	3/2013	Liu et al.
8,027,729 B2	9/2011	Sunagawa et al.	8,406,879 B2	3/2013	Shuros et al.
8,032,219 B2	10/2011	Neumann et al.	8,406,886 B2	3/2013	Gaunt et al.
8,036,743 B2	10/2011	Savage et al.	8,412,352 B2	4/2013	Griswold et al.
8,046,079 B2	10/2011	Bange et al.	8,417,340 B2	4/2013	Goossen
8,046,080 B2	10/2011	Von Arx et al.	8,417,341 B2	4/2013	Freeberg
8,050,297 B2	11/2011	Delmain et al.	8,423,149 B2	4/2013	Hennig
8,050,759 B2	11/2011	Stegemann et al.	8,428,722 B2	4/2013	Verhoef et al.
8,050,774 B2	11/2011	Kveen et al.	8,433,402 B2	4/2013	Ruben et al.
8,055,345 B2	11/2011	Li et al.	8,433,409 B2	4/2013	Johnson et al.
8,055,350 B2	11/2011	Roberts	8,433,420 B2	4/2013	Bange et al.
8,060,212 B1	11/2011	Rios et al.	8,447,412 B2	5/2013	Dal Molin et al.
8,065,018 B2	11/2011	Haubrich et al.	8,452,413 B2	5/2013	Young et al.
8,073,542 B2	12/2011	Doerr	8,457,740 B2	6/2013	Osche
8,078,278 B2	12/2011	Penner	8,457,742 B2	6/2013	Jacobson
8,078,283 B2	12/2011	Cowan et al.	8,457,744 B2	6/2013	Janzig et al.
8,095,123 B2	1/2012	Gray	8,457,761 B2	6/2013	Warier
8,102,789 B2	1/2012	Rosar et al.	8,478,407 B2	7/2013	Demmer et al.
8,103,359 B2	1/2012	Reddy	8,478,408 B2	7/2013	Hastings et al.
8,103,361 B2	1/2012	Moser	8,478,431 B2	7/2013	Griswold et al.
8,112,148 B2	2/2012	Giftakis et al.	8,494,632 B2	7/2013	Sun et al.
8,114,021 B2	2/2012	Robertson et al.	8,504,156 B2	8/2013	Bonner et al.
8,121,680 B2	2/2012	Falkenberg et al.	8,509,910 B2	8/2013	Sowder et al.
8,123,684 B2	2/2012	Zdeblick	8,515,559 B2	8/2013	Roberts et al.
8,126,545 B2	2/2012	Flach et al.	8,525,340 B2	9/2013	Eckhardt et al.
8,128,569 B1	3/2012	Mason et al.	8,527,068 B2	9/2013	Ostroff
8,131,334 B2	3/2012	Lu et al.	8,532,790 B2	9/2013	Griswold
8,140,161 B2	3/2012	Willerton et al.	8,538,526 B2	9/2013	Stahmann et al.
8,150,521 B2	4/2012	Crowley et al.	8,541,131 B2	9/2013	Lund et al.
8,160,672 B2	4/2012	Kim et al.	8,543,205 B2	9/2013	Ostroff
8,160,702 B2	4/2012	Mann et al.	8,547,248 B2	10/2013	Zdeblick et al.
8,160,704 B2	4/2012	Freeberg	8,548,605 B2 *	10/2013	Ollivier A61N 1/0587 607/127
8,165,694 B2	4/2012	Carbanaru et al.	8,554,333 B2	10/2013	Wu et al.
8,175,715 B1	5/2012	Cox	8,565,882 B2	10/2013	Matos
8,180,451 B2	5/2012	Hickman et al.	8,565,897 B2	10/2013	Regnier et al.
8,185,213 B2	5/2012	Kveen et al.	8,571,678 B2	10/2013	Wang
8,187,161 B2	5/2012	Li et al.	8,577,327 B2	11/2013	Makdissi et al.
8,195,293 B2	6/2012	Limousin et al.	8,588,926 B2	11/2013	Moore et al.
8,204,595 B2	6/2012	Pianca et al.	8,612,002 B2	12/2013	Faltys et al.
8,204,605 B2	6/2012	Hastings et al.	8,615,310 B2	12/2013	Khairkhahan et al.
8,209,014 B2	6/2012	Doerr	8,626,280 B2	1/2014	Allavatam et al.
8,214,043 B2	7/2012	Matos	8,626,294 B2	1/2014	Sheldon et al.
8,224,244 B2	7/2012	Kim et al.	8,634,908 B2	1/2014	Cowan
8,229,556 B2	7/2012	Li	8,634,912 B2	1/2014	Bornzin et al.
8,233,985 B2	7/2012	Bulkes et al.	8,634,919 B1	1/2014	Hou et al.
8,265,748 B2	9/2012	Liu et al.	8,639,335 B2	1/2014	Peichel et al.
8,265,757 B2	9/2012	Mass et al.	8,644,934 B2	2/2014	Hastings et al.
8,262,578 B1	10/2012	Bharmi et al.	8,649,859 B2	2/2014	Smith et al.
8,280,521 B2	10/2012	Haubrich et al.	8,670,842 B1	3/2014	Bornzin et al.
8,285,387 B2	10/2012	Utsi et al.	8,676,319 B2	3/2014	Knoll
8,290,598 B2	10/2012	Boon et al.	8,676,335 B2	3/2014	Katoozi et al.
8,290,600 B2	10/2012	Hastings et al.	8,700,173 B2	4/2014	Edlund
8,295,939 B2	10/2012	Jacobson	8,700,181 B2	4/2014	Bornzin et al.
8,301,254 B2	10/2012	Mosesov et al.	8,705,599 B2	4/2014	dal Molin et al.
8,315,701 B2	11/2012	Cowan et al.	8,718,766 B2	5/2014	Wahlberg
8,315,708 B2	11/2012	Berthelsdorf et al.	8,718,773 B2	5/2014	Willis et al.
8,321,021 B2	11/2012	Kisker et al.	8,725,260 B2	5/2014	Shuros et al.
8,321,036 B2	11/2012	Brockway et al.	8,738,133 B2	5/2014	Shuros et al.
8,332,036 B2	12/2012	Hastings et al.	8,738,147 B2	5/2014	Hastings et al.
8,335,563 B2	12/2012	Stessman	8,744,555 B2	6/2014	Allavatam et al.
8,335,568 B2	12/2012	Heruth et al.	8,744,572 B1	6/2014	Greenhut et al.
8,340,750 B2	12/2012	Prakash et al.	8,747,314 B2	6/2014	Stahmann et al.
8,340,780 B2	12/2012	Hastings et al.	8,755,884 B2	6/2014	Demmer et al.
8,352,025 B2	1/2013	Jacobson	8,758,365 B2	6/2014	Bonner et al.
8,352,028 B2	1/2013	Wenger	8,768,483 B2	7/2014	Schmitt et al.
8,352,038 B2	1/2013	Mao et al.	8,774,572 B2	7/2014	Hamamoto
8,359,098 B2	1/2013	Lund et al.	8,781,605 B2	7/2014	Bornzin et al.
8,364,261 B2	1/2013	Stubbs et al.	8,788,035 B2	7/2014	Jacobson
8,364,276 B2	1/2013	Willis	8,788,053 B2	7/2014	Jacobson
8,369,959 B2	2/2013	Meskens	8,798,740 B2	8/2014	Samade et al.
			8,798,745 B2	8/2014	Jacobson
			8,798,762 B2	8/2014	Fain et al.
			8,798,770 B2	8/2014	Reddy

(56)

References Cited

U.S. PATENT DOCUMENTS

8,805,505	B1	8/2014	Roberts	9,492,677	B2	11/2016	Greenhut et al.
8,805,528	B2	8/2014	Corndorf	9,511,233	B2	12/2016	Sambelashvili
8,812,109	B2	8/2014	Blomqvist et al.	9,511,236	B2	12/2016	Varady et al.
8,818,504	B2	8/2014	Bodner et al.	9,511,237	B2	12/2016	Deterre et al.
8,827,913	B2	9/2014	Havel et al.	2002/0032470	A1	3/2002	Linberg
8,831,747	B1	9/2014	Min et al.	2002/0035376	A1	3/2002	Bardy et al.
8,855,789	B2	10/2014	Jacobson	2002/0035377	A1	3/2002	Bardy et al.
8,868,186	B2	10/2014	Kroll	2002/0035378	A1	3/2002	Bardy et al.
8,886,339	B2	11/2014	Faltys et al.	2002/0035380	A1	3/2002	Rissmann et al.
8,903,473	B2	12/2014	Rogers et al.	2002/0035381	A1	3/2002	Bardy et al.
8,903,500	B2	12/2014	Smith et al.	2002/0042629	A1	4/2002	Bardy et al.
8,903,513	B2	12/2014	Ollivier	2002/0042630	A1	4/2002	Bardy et al.
8,909,336	B2	12/2014	Navarro-Paredes et al.	2002/0042634	A1	4/2002	Bardy et al.
8,914,131	B2	12/2014	Bornzin et al.	2002/0049475	A1	4/2002	Bardy et al.
8,923,795	B2	12/2014	Makdissi et al.	2002/0052636	A1	5/2002	Bardy et al.
8,923,963	B2	12/2014	Bonner et al.	2002/0068958	A1	6/2002	Bardy et al.
8,938,300	B2	1/2015	Rosero	2002/0072773	A1	6/2002	Bardy et al.
8,942,806	B2	1/2015	Sheldon et al.	2002/0082665	A1	6/2002	Haller et al.
8,958,892	B2	2/2015	Khairkahan et al.	2002/0091414	A1	7/2002	Bardy et al.
8,977,358	B2	3/2015	Ewert et al.	2002/0095196	A1	7/2002	Linberg
8,989,873	B2	3/2015	Locsin	2002/0099423	A1	7/2002	Berg et al.
8,996,109	B2	3/2015	Karst et al.	2002/0103510	A1	8/2002	Bardy et al.
9,002,467	B2	4/2015	Smith et al.	2002/0107545	A1	8/2002	Rissmann et al.
9,008,776	B2	4/2015	Cowan et al.	2002/0107546	A1	8/2002	Ostroff et al.
9,008,777	B2	4/2015	Dianaty et al.	2002/0107547	A1	8/2002	Erlinger et al.
9,014,818	B2	4/2015	Deterre et al.	2002/0107548	A1	8/2002	Bardy et al.
9,017,341	B2	4/2015	Bornzin et al.	2002/0107549	A1	8/2002	Bardy et al.
9,020,611	B2	4/2015	Khairkahan et al.	2002/0107559	A1	8/2002	Sanders et al.
9,037,262	B2	5/2015	Regnier et al.	2002/0120299	A1	8/2002	Ostroff et al.
9,042,984	B2	5/2015	Demmer et al.	2002/0173830	A1	11/2002	Starkweather et al.
9,072,911	B2	7/2015	Hastings et al.	2002/0193846	A1	12/2002	Pool et al.
9,072,913	B2	7/2015	Jacobson	2003/0009203	A1	1/2003	Lebel et al.
9,155,882	B2	10/2015	Grubac et al.	2003/0028082	A1	2/2003	Thompson
9,168,372	B2	10/2015	Fain	2003/0040779	A1	2/2003	Engmark et al.
9,168,380	B1	10/2015	Greenhut et al.	2003/0041866	A1	3/2003	Linberg et al.
9,168,383	B2	10/2015	Jacobson et al.	2003/0045805	A1	3/2003	Sheldon et al.
9,180,285	B2	11/2015	Moore et al.	2003/0088278	A1	5/2003	Bardy et al.
9,192,774	B2	11/2015	Jacobson	2003/0097153	A1	5/2003	Bardy et al.
9,205,225	B2	12/2015	Khairkahan et al.	2003/0105497	A1	6/2003	Zhu et al.
9,216,285	B1	12/2015	Boling et al.	2003/0114908	A1	6/2003	Flach
9,216,293	B2	12/2015	Berthiaume et al.	2003/0144701	A1	7/2003	Mehra et al.
9,216,298	B2	12/2015	Jacobson	2003/0163054	A1	8/2003	Dekker
9,227,077	B2	1/2016	Jacobson	2003/0187460	A1	10/2003	Chin et al.
9,238,145	B2	1/2016	Wenzel et al.	2003/0187461	A1	10/2003	Chin
9,242,102	B2	1/2016	Khairkahan et al.	2004/0024435	A1	2/2004	Leckrone et al.
9,242,113	B2	1/2016	Smith et al.	2004/0068302	A1	4/2004	Rodgers et al.
9,248,300	B2	2/2016	Rys et al.	2004/0087938	A1	5/2004	Leckrone et al.
9,265,436	B2	2/2016	Min et al.	2004/0088035	A1	5/2004	Guenst et al.
9,265,962	B2	2/2016	Dianaty et al.	2004/0102830	A1	5/2004	Williams
9,272,155	B2	3/2016	Ostroff	2004/0127959	A1	7/2004	Amundson et al.
9,278,218	B2	3/2016	Karst et al.	2004/0133242	A1	7/2004	Chapman et al.
9,278,229	B1	3/2016	Reinke et al.	2004/0147969	A1	7/2004	Mann et al.
9,283,381	B2	3/2016	Grubac et al.	2004/0147973	A1	7/2004	Hauser
9,283,382	B2	3/2016	Berthiaume et al.	2004/0167558	A1	8/2004	Igo et al.
9,289,612	B1	3/2016	Sambelashvili et al.	2004/0167587	A1	8/2004	Thompson
9,302,115	B2	4/2016	Molin et al.	2004/0172071	A1	9/2004	Bardy et al.
9,333,364	B2	5/2016	Echt et al.	2004/0172077	A1	9/2004	Chinchoy
9,358,387	B2	6/2016	Suwito et al.	2004/0172104	A1	9/2004	Berg et al.
9,358,400	B2	6/2016	Jacobson	2004/0176817	A1	9/2004	Wahlstrand et al.
9,364,675	B2	6/2016	Deterre et al.	2004/0176818	A1	9/2004	Wahlstrand et al.
9,370,663	B2	6/2016	Moulder	2004/0176830	A1	9/2004	Fang
9,375,580	B2	6/2016	Bonner et al.	2004/0186529	A1	9/2004	Bardy et al.
9,375,581	B2	6/2016	Baru et al.	2004/0204673	A1	10/2004	Flaherty
9,381,365	B2	7/2016	Kibler et al.	2004/0210292	A1	10/2004	Bardy et al.
9,393,424	B2	7/2016	Demmer et al.	2004/0210293	A1	10/2004	Bardy et al.
9,393,436	B2	7/2016	Doerr	2004/0210294	A1	10/2004	Bardy et al.
9,399,139	B2	7/2016	Demmer et al.	2004/0215308	A1	10/2004	Bardy et al.
9,399,140	B2	7/2016	Cho et al.	2004/0220624	A1	11/2004	Ritscher et al.
9,409,033	B2	8/2016	Jacobson	2004/0220626	A1	11/2004	Wagner
9,427,594	B1	8/2016	Bornzin et al.	2004/0220639	A1	11/2004	Mulligan et al.
9,433,368	B2	9/2016	Stahmann et al.	2004/0249431	A1	12/2004	Ransbury et al.
9,433,780	B2	9/2016	Régnier et al.	2004/0260346	A1	12/2004	Overall et al.
9,492,668	B2	11/2016	Sheldon et al.	2004/0260348	A1	12/2004	Bakken et al.
9,492,669	B2	11/2016	Demmer et al.	2004/0267303	A1	12/2004	Guenst
9,492,674	B2	11/2016	Schmidt et al.	2005/0061320	A1	3/2005	Lee et al.
				2005/0070962	A1	3/2005	Echt et al.
				2005/0102003	A1	5/2005	Grabek et al.
				2005/0149138	A1	7/2005	Min et al.
				2005/0165466	A1	7/2005	Morris et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2005/0182465 A1	8/2005	Ness	2008/0306359 A1	12/2008	Zdeblick et al.
2005/0203410 A1	9/2005	Jenkins	2009/0018599 A1	1/2009	Hastings et al.
2005/0283208 A1	12/2005	Von Arx et al.	2009/0024180 A1	1/2009	Kisker et al.
2005/0288743 A1	12/2005	Ahn et al.	2009/0036941 A1	2/2009	Corbucci
2006/0042830 A1	3/2006	Maghribi et al.	2009/0048646 A1	2/2009	Katoozi et al.
2006/0052829 A1	3/2006	Sun et al.	2009/0062895 A1	3/2009	Stahmann et al.
2006/0052830 A1	3/2006	Spinelli et al.	2009/0082827 A1	3/2009	Kveen et al.
2006/0064135 A1	3/2006	Brockway	2009/0082828 A1	3/2009	Ostroff
2006/0064149 A1	3/2006	Belacazar et al.	2009/0088813 A1	4/2009	Brockway et al.
2006/0085039 A1	4/2006	Hastings et al.	2009/0131907 A1	5/2009	Chin et al.
2006/0085041 A1	4/2006	Hastings et al.	2009/0135886 A1	5/2009	Robertson et al.
2006/0085042 A1	4/2006	Hastings et al.	2009/0143835 A1	6/2009	Pastore et al.
2006/0095078 A1	5/2006	Tronnes	2009/0171408 A1	7/2009	Solem
2006/0106442 A1	5/2006	Richardson et al.	2009/0171414 A1	7/2009	Kelly et al.
2006/0116746 A1	6/2006	Chin	2009/0177069 A1	7/2009	Razavi
2006/0135999 A1	6/2006	Bodner et al.	2009/0204163 A1	8/2009	Shuros et al.
2006/0136004 A1	6/2006	Cowan et al.	2009/0204170 A1	8/2009	Hastings et al.
2006/0161061 A1	7/2006	Echt et al.	2009/0210024 A1	8/2009	M
2006/0161211 A1	7/2006	Thompson et al.	2009/0216292 A1	8/2009	Pless et al.
2006/0178586 A1	8/2006	Dobak	2009/0234407 A1	9/2009	Hastings et al.
2006/0200002 A1	9/2006	Guenst	2009/0234411 A1	9/2009	Sambelashvili et al.
2006/0206151 A1	9/2006	Lu	2009/0266573 A1	10/2009	Engmark et al.
2006/0212079 A1	9/2006	Routh et al.	2009/0275998 A1	11/2009	Burnes et al.
2006/0241701 A1	10/2006	Markowitz et al.	2009/0275999 A1	11/2009	Burnes et al.
2006/0241705 A1	10/2006	Neumann et al.	2009/0299447 A1	12/2009	Jensen et al.
2006/0247672 A1	11/2006	Vidlund et al.	2010/0013668 A1	1/2010	Kantervik
2006/0259088 A1	11/2006	Pastore et al.	2010/0016911 A1	1/2010	Willis et al.
2006/0265018 A1	11/2006	Smith et al.	2010/0023085 A1	1/2010	Wu et al.
2007/0004979 A1	1/2007	Wojciechowicz et al.	2010/0030061 A1	2/2010	Canfield et al.
2007/0016098 A1	1/2007	Kim et al.	2010/0030327 A1	2/2010	Chatel
2007/0027508 A1	2/2007	Cowan	2010/0042108 A1	2/2010	Hibino
2007/0032749 A1	2/2007	Overall et al.	2010/0056871 A1	3/2010	Govari et al.
2007/0078490 A1	4/2007	Cowan et al.	2010/0063375 A1	3/2010	Kassab et al.
2007/0088394 A1*	4/2007	Jacobson A61N 1/3708 607/4	2010/0063562 A1	3/2010	Cowan et al.
2007/0088396 A1	4/2007	Jacobson	2010/0094367 A1	4/2010	Sen
2007/0088397 A1	4/2007	Jacobson	2010/0106030 A1	4/2010	Mason
2007/0088398 A1	4/2007	Jacobson	2010/0114209 A1	5/2010	Krause et al.
2007/0088405 A1	4/2007	Jacobson	2010/0114214 A1	5/2010	Morelli et al.
2007/0135882 A1	6/2007	Drasler et al.	2010/0125281 A1	5/2010	Jacobson et al.
2007/0135883 A1	6/2007	Drasler et al.	2010/0168761 A1	7/2010	Kassab et al.
2007/0150037 A1	6/2007	Hastings et al.	2010/0168819 A1	7/2010	Freeberg
2007/0150038 A1	6/2007	Hastings et al.	2010/0198288 A1	8/2010	Ostroff
2007/0156190 A1	7/2007	Cinbis	2010/0198304 A1	8/2010	Wang
2007/0219525 A1	9/2007	Gelfand et al.	2010/0217367 A1	8/2010	Belson
2007/0219590 A1	9/2007	Hastings et al.	2010/0228308 A1	9/2010	Cowan et al.
2007/0225545 A1	9/2007	Ferrari	2010/0234906 A1	9/2010	Koh
2007/0233206 A1	10/2007	Frikart et al.	2010/0234924 A1	9/2010	Willis
2007/0239244 A1	10/2007	Morgan et al.	2010/0241185 A1	9/2010	Mahapatra et al.
2007/0255376 A1	11/2007	Michels et al.	2010/0249729 A1	9/2010	Morris et al.
2007/0276444 A1	11/2007	Gelbart et al.	2010/0286744 A1	11/2010	Echt et al.
2007/0293900 A1	12/2007	Sheldon et al.	2010/0312309 A1	12/2010	Harding
2007/0293904 A1	12/2007	Gelbart et al.	2011/0022113 A1	1/2011	Zdeblick et al.
2008/0004663 A1	1/2008	Jorgenson	2011/0071586 A1	3/2011	Jacobson
2008/0021505 A1	1/2008	Hastings et al.	2011/0077708 A1	3/2011	Ostroff
2008/0021519 A1	1/2008	De Geest et al.	2011/0112600 A1	5/2011	Cowan et al.
2008/0021532 A1	1/2008	Kveen et al.	2011/0118588 A1	5/2011	Komblau et al.
2008/0065183 A1	3/2008	Whitehurst et al.	2011/0118810 A1	5/2011	Cowan et al.
2008/0065185 A1	3/2008	Worley	2011/0137187 A1	6/2011	Yang et al.
2008/0071318 A1	3/2008	Brooke et al.	2011/0144720 A1	6/2011	Cowan et al.
2008/0109054 A1	5/2008	Hastings et al.	2011/0152970 A1	6/2011	Jollota et al.
2008/0119911 A1	5/2008	Rosero	2011/0160558 A1	6/2011	Rassatt et al.
2008/0130670 A1	6/2008	Kim et al.	2011/0160565 A1	6/2011	Stubbs et al.
2008/0154139 A1	6/2008	Shuros et al.	2011/0160801 A1	6/2011	Markowitz et al.
2008/0154322 A1	6/2008	Jackson et al.	2011/0160806 A1	6/2011	Lyden et al.
2008/0228234 A1	9/2008	Stancer	2011/0166620 A1	7/2011	Cowan et al.
2008/0234771 A1	9/2008	Chinchoy et al.	2011/0166621 A1	7/2011	Cowan et al.
2008/0243217 A1	10/2008	Wildon	2011/0184491 A1	7/2011	Kivi
2008/0269814 A1	10/2008	Rosero	2011/0190835 A1	8/2011	Brockway et al.
2008/0269825 A1	10/2008	Chinchoy et al.	2011/0208260 A1	8/2011	Jacobson
2008/0275518 A1	11/2008	Ghanem et al.	2011/0218587 A1	9/2011	Jacobson
2008/0275519 A1	11/2008	Ghanem et al.	2011/0230734 A1	9/2011	Fain et al.
2008/0288039 A1	11/2008	Reddy	2011/0237967 A1	9/2011	Moore et al.
2008/0294208 A1	11/2008	Willis et al.	2011/0245890 A1	10/2011	Brisben et al.
2008/0294210 A1	11/2008	Rosero	2011/0251660 A1	10/2011	Griswold
			2011/0251662 A1	10/2011	Griswold et al.
			2011/0270099 A1	11/2011	Ruben et al.
			2011/0270339 A1	11/2011	Murray, III et al.
			2011/0270340 A1	11/2011	Pellegrini et al.
			2011/0276102 A1	11/2011	Cohen

(56)

References Cited

U.S. PATENT DOCUMENTS

2011/0282423 A1	11/2011	Jacobson	2013/0197609 A1	8/2013	Moore et al.
2012/0004527 A1	1/2012	Thompson et al.	2013/0231710 A1	9/2013	Jacobson
2012/0029323 A1	2/2012	Zhao	2013/0238072 A1	9/2013	Deterre et al.
2012/0041508 A1	2/2012	Rousso et al.	2013/0238073 A1	9/2013	Makdissi et al.
2012/0059433 A1	3/2012	Cowan et al.	2013/0253342 A1	9/2013	Griswold et al.
2012/0059436 A1	3/2012	Fontaine et al.	2013/0253343 A1	9/2013	Waldhauser et al.
2012/0065500 A1	3/2012	Rogers et al.	2013/0253344 A1	9/2013	Griswold et al.
2012/0078322 A1	3/2012	Dal Molin et al.	2013/0253345 A1	9/2013	Griswold et al.
2012/0089198 A1	4/2012	Ostroff	2013/0253346 A1	9/2013	Griswold et al.
2012/0093245 A1	4/2012	Makdissi et al.	2013/0253347 A1	9/2013	Griswold et al.
2012/0095521 A1	4/2012	Hintz	2013/0261497 A1	10/2013	Pertijis et al.
2012/0095539 A1	4/2012	Khairkahan et al.	2013/0265144 A1	10/2013	Banna et al.
2012/0101540 A1	4/2012	O'Brien et al.	2013/0268042 A1	10/2013	Hastings et al.
2012/0101553 A1	4/2012	Reddy	2013/0274828 A1	10/2013	Willis
2012/0109148 A1	5/2012	Bonner et al.	2013/0274847 A1	10/2013	Ostroff
2012/0109149 A1	5/2012	Bonner et al.	2013/0282070 A1	10/2013	Cowan et al.
2012/0109236 A1	5/2012	Jacobson et al.	2013/0282073 A1	10/2013	Cowan et al.
2012/0109259 A1	5/2012	Bond et al.	2013/0296727 A1	11/2013	Sullivan et al.
2012/0116489 A1	5/2012	Khairkahan et al.	2013/0303872 A1	11/2013	Taff et al.
2012/0150251 A1	6/2012	Giftakis et al.	2013/0324825 A1	12/2013	Ostroff et al.
2012/0158111 A1	6/2012	Khairkahan et al.	2013/0325081 A1	12/2013	Karst et al.
2012/0165827 A1	6/2012	Khairkahan et al.	2013/0345770 A1	12/2013	Dianaty et al.
2012/0172688 A1	7/2012	Mason et al.	2014/0012344 A1	1/2014	Hastings et al.
2012/0172690 A1	7/2012	Anderson et al.	2014/0018876 A1	1/2014	Ostroff
2012/0172891 A1	7/2012	Lee	2014/0018877 A1	1/2014	Demmer et al.
2012/0172892 A1	7/2012	Grubac et al.	2014/0031836 A1	1/2014	Ollivier
2012/0172942 A1	7/2012	Berg	2014/0039570 A1	2/2014	Carroll et al.
2012/0197350 A1	8/2012	Roberts et al.	2014/0039591 A1	2/2014	Drasler et al.
2012/0197373 A1	8/2012	Khairkahan et al.	2014/0043146 A1	2/2014	Makdissi et al.
2012/0215285 A1	8/2012	Tahmasian et al.	2014/0046395 A1	2/2014	Regnier et al.
2012/0232565 A1	9/2012	Kveen et al.	2014/0046420 A1	2/2014	Moore et al.
2012/0277600 A1	11/2012	Greenhut	2014/0058240 A1	2/2014	Mothilal et al.
2012/0277606 A1	11/2012	Ellingson et al.	2014/0058494 A1	2/2014	Ostroff et al.
2012/0283795 A1	11/2012	Stancer et al.	2014/0074114 A1	3/2014	Khairkahan et al.
2012/0283807 A1	11/2012	Deterre et al.	2014/0074186 A1	3/2014	Faltys et al.
2012/0290025 A1	11/2012	Keimel	2014/0094891 A1	4/2014	Pare et al.
2012/0296381 A1	11/2012	Matos	2014/0100627 A1	4/2014	Min
2012/0303082 A1	11/2012	Dong et al.	2014/0107723 A1	4/2014	Hou et al.
2012/0316613 A1	12/2012	Keefe et al.	2014/0121719 A1	5/2014	Bonner et al.
2013/0012151 A1	1/2013	Hankins	2014/0121720 A1	5/2014	Bonner et al.
2013/0023975 A1	1/2013	Locsin	2014/0121722 A1	5/2014	Sheldon et al.
2013/0035748 A1	2/2013	Bonner et al.	2014/0128935 A1	5/2014	Kumar et al.
2013/0041422 A1	2/2013	Jacobson	2014/0135865 A1	5/2014	Hastings et al.
2013/0053908 A1	2/2013	Smith et al.	2014/0142648 A1	5/2014	Smith et al.
2013/0053915 A1	2/2013	Holmstrom et al.	2014/0148675 A1	5/2014	Nordstrom et al.
2013/0053921 A1	2/2013	Bonner et al.	2014/0148815 A1	5/2014	Wenzel et al.
2013/0060298 A1	3/2013	Splett et al.	2014/0155950 A1	6/2014	Hastings et al.
2013/0066169 A1	3/2013	Rys et al.	2014/0169162 A1	6/2014	Romano et al.
2013/0072770 A1	3/2013	Rao et al.	2014/0172060 A1	6/2014	Bornzin et al.
2013/0079798 A1	3/2013	Tran et al.	2014/0180306 A1	6/2014	Grubac et al.
2013/0079861 A1	3/2013	Reinert et al.	2014/0180366 A1	6/2014	Edlund
2013/0085350 A1	4/2013	Schugt et al.	2014/0207149 A1	7/2014	Hastings et al.
2013/0085403 A1	4/2013	Gunderson et al.	2014/0207210 A1	7/2014	Willis et al.
2013/0085550 A1	4/2013	Polefko et al.	2014/0214104 A1	7/2014	Greenhut et al.
2013/0096649 A1	4/2013	Martin et al.	2014/0222098 A1	8/2014	Baru et al.
2013/0103047 A1	4/2013	Steingisser et al.	2014/0222109 A1	8/2014	Moulder
2013/0103109 A1	4/2013	Jacobson	2014/0228913 A1	8/2014	Molin et al.
2013/0110008 A1	5/2013	Bourget et al.	2014/0236172 A1	8/2014	Hastings et al.
2013/0110127 A1	5/2013	Bornzin et al.	2014/0243848 A1	8/2014	Auricchio et al.
2013/0110192 A1	5/2013	Tran et al.	2014/0255298 A1	9/2014	Cole et al.
2013/0110219 A1	5/2013	Bornzin et al.	2014/0257324 A1	9/2014	Fain
2013/0116529 A1	5/2013	Min et al.	2014/0257422 A1	9/2014	Herken
2013/0116738 A1	5/2013	Samade et al.	2014/0257444 A1	9/2014	Cole et al.
2013/0116740 A1	5/2013	Bornzin et al.	2014/0276929 A1	9/2014	Foster et al.
2013/0116741 A1	5/2013	Bornzin et al.	2014/0303704 A1	10/2014	Suwito et al.
2013/0123872 A1	5/2013	Bornzin et al.	2014/0309706 A1	10/2014	Jacobson
2013/0123875 A1	5/2013	Varady et al.	2014/0379041 A1	12/2014	Foster
2013/0131591 A1	5/2013	Berthiaume et al.	2015/0025612 A1	1/2015	Haasl et al.
2013/0131693 A1	5/2013	Berthiaume et al.	2015/0032007 A1 *	1/2015	Ottevanger A61B 5/6869 600/465
2013/0138006 A1	5/2013	Bornzin et al.	2015/0039041 A1	2/2015	Smith et al.
2013/0150695 A1	6/2013	Biela et al.	2015/0051609 A1	2/2015	Schmidt et al.
2013/0150911 A1	6/2013	Perschbacher et al.	2015/0051610 A1	2/2015	Schmidt et al.
2013/0150912 A1	6/2013	Perschbacher et al.	2015/0051611 A1	2/2015	Schmidt et al.
2013/0184776 A1	7/2013	Shuros et al.	2015/0051612 A1	2/2015	Schmidt et al.
2013/0196703 A1	8/2013	Masoud et al.	2015/0051613 A1	2/2015	Schmidt et al.
			2015/0051614 A1	2/2015	Schmidt et al.
			2015/0051615 A1	2/2015	Schmidt et al.
			2015/0051616 A1	2/2015	Haasl et al.

(56)

References Cited**U.S. PATENT DOCUMENTS**

2015/0051682	A1	2/2015	Schmidt et al.	
2015/0057520	A1	2/2015	Foster et al.	
2015/0057558	A1	2/2015	Stahmann et al.	
2015/0057721	A1	2/2015	Stahmann et al.	
2015/0088155	A1	3/2015	Stahmann et al.	
2015/0105836	A1	4/2015	Bonner et al.	
2015/0157861	A1	6/2015	Aghassian	
2015/0173655	A1	6/2015	Demmer et al.	
2015/0190638	A1	7/2015	Smith et al.	
2015/0196756	A1	7/2015	Stahmann et al.	
2015/0196757	A1	7/2015	Stahmann et al.	
2015/0196758	A1	7/2015	Stahmann et al.	
2015/0196769	A1	7/2015	Stahmann et al.	
2015/0217119	A1	8/2015	Nikolski et al.	
2015/0221898	A1	8/2015	Chi et al.	
2015/0224315	A1	8/2015	Stahmann	
2015/0224320	A1	8/2015	Stahmann	
2015/0258345	A1	9/2015	Smith et al.	
2015/0290468	A1	10/2015	Zhang	
2015/0297905	A1	10/2015	Greenhut et al.	
2015/0297907	A1	10/2015	Zhang	
2015/0305637	A1	10/2015	Greenhut et al.	
2015/0305638	A1	10/2015	Zhang	
2015/0305639	A1	10/2015	Greenhut et al.	
2015/0305640	A1	10/2015	Reinke et al.	
2015/0305641	A1	10/2015	Stadler et al.	
2015/0305642	A1	10/2015	Reinke et al.	
2015/0306374	A1	10/2015	Seifert et al.	
2015/0306375	A1	10/2015	Marshall et al.	
2015/0306406	A1	10/2015	Crutchfield et al.	
2015/0306407	A1	10/2015	Crutchfield et al.	
2015/0306408	A1	10/2015	Greenhut et al.	
2015/0321016	A1	11/2015	O'Brien et al.	
2015/0328459	A1	11/2015	Chin et al.	
2016/0015322	A1	1/2016	Anderson et al.	
2016/0023000	A1*	1/2016	Cho	A61N 1/36578 607/18
2016/0030757	A1	2/2016	Jacobson	
2016/0033177	A1	2/2016	Barot et al.	
2016/0121127	A1	5/2016	Klimovitch et al.	
2016/0121128	A1	5/2016	Fishler et al.	
2016/0121129	A1	5/2016	Persson et al.	
2016/0213919	A1	7/2016	Suwito et al.	
2016/0213937	A1	7/2016	Reinke et al.	
2016/0213939	A1	7/2016	Carney et al.	
2016/0228026	A1	8/2016	Jackson	
2016/0317825	A1	11/2016	Jacobson	
2016/0331888	A1*	11/2016	Koolbergen	A61M 1/0058

FOREIGN PATENT DOCUMENTS

AU	2014203793	A1	7/2014
CA	1003904	A1	1/1977
CN	202933393	U	5/2013
EP	0362611	A1	4/1990
EP	503823	A2	9/1992
EP	1702648	A2	9/2006
EP	1904166	B1	6/2011
EP	2433675	B1	1/2013

EP	2441491	B1	1/2013
EP	2452721	B1	11/2013
EP	1948296	B1	1/2014
EP	2662113	A3	1/2014
EP	2471452	B1	12/2014
EP	2760541	B1	5/2016
EP	2833966	B1	5/2016
JP	2000051373	A	2/2000
JP	2002502640	A	1/2002
JP	2004512105	A	4/2004
JP	2005508208	A	3/2005
JP	2005245215	A	9/2005
JP	2008540040	A	11/2008
JP	5199867	B2	2/2013
WO	9500202	A1	1/1995
WO	9636134	A1	11/1996
WO	9724981	A2	7/1997
WO	9826840	A1	6/1998
WO	9939767	A1	8/1999
WO	0234330	A2	1/2003
WO	02098282	A2	5/2003
WO	2004066825	A2	8/2004
WO	2005000206	A3	4/2005
WO	2005042089	A1	5/2005
WO	2006065394	A1	6/2006
WO	2006086435	A3	8/2006
WO	2006113659	A1	10/2006
WO	2006124833	A2	11/2006
WO	2006124833	A3	5/2007
WO	2007075974	A2	7/2007
WO	2009006531	A1	1/2009
WO	2012054102	A1	4/2012
WO	2013080038	A2	6/2013
WO	2013098644	A3	8/2013
WO	2013184787	A1	12/2013
WO	2014120769	A1	8/2014

OTHER PUBLICATIONS

Hachisuka et al., "Development and Performance Analysis of an Intra-Body Communication Device," The 12th International Conference on Solid State Sensors, Actuators and Microsystems, vol. 4A1.3, pp. 1722-1725, 2003.

Seyedi et al., "A Survey on Intrabody Communications for Body Area Network Application," IEEE Transactions on Biomedical Engineering, vol. 60(8): 2067-2079, 2013.

Wegmüller, "Intra-Body Communication for Biomedical Sensor Networks," Diss. ETH, No. 17323, 1-173, 2007.

Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, dated Jan. 29, 2016, 15 pages.

Spickler et al., "Totally Self-Contained Intracardiac Pacemaker," Journal of Electrocardiology, vol. 3(3&4): 324-331, 1970.

"Instructions for Use System 1, Leadless Cardiac Pacemaker (LCP) and Delivery Catheter," Nanostim Leadless Pacemakers, pp. 1-28, 2013.

International Search Report and Written Opinion for Application No. PCT/US2016/048180, 11 pages, dated Dec. 5, 2016.

* cited by examiner




Figure 1




Figure 2




Figure 3




Figure 4




FIG. 5




Figure 6




Figure 7




Figure 8




Figure 9

1

SYSTEM AND METHOD FOR DETECTING TAMPONADE

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 62/211,333 filed on Aug. 28, 2015, the disclosure of which is incorporated herein by reference.

TECHNICAL FIELD

The present disclosure generally relates to systems, devices, and methods for detecting a tamponade condition, and more particularly, to systems, devices, and methods for detecting a tamponade condition using one or more signals sensed by an implanted medical device.

BACKGROUND

Pacing instruments can be used to treat patients suffering from various heart conditions that result in a reduced ability of the heart to deliver sufficient amounts of blood to a patient's body. These heart conditions may lead to rapid, irregular, and/or inefficient heart contractions. To help alleviate some of these conditions, various devices (e.g., pacemakers, defibrillators, etc.) may be implanted in a patient's body. Such devices may monitor and provide electrical stimulation to the heart to help the heart operate in a more normal, efficient and/or safe manner. In some cases, such devices may be attached, at least partially, to the heart.

SUMMARY

The present disclosure generally relates to systems, devices, and methods for detecting a tamponade condition, and more particularly, to systems, devices, and methods for detecting a tamponade condition using one or more signals sensed by an implanted medical device. In a first illustrative embodiment, a leadless cardiac pacemaker for use in pacing a patient's heart may comprise a plurality of electrodes, an accelerometer for providing an accelerometer signal. The leadless cardiac pacemaker may further comprise a controller operatively coupled to the plurality of electrodes and the accelerometer. The leadless cardiac pacemaker may be implanted into a patient's heart and attached to a wall of the patient's heart using one or more fixation elements. In some instances, fixing the fixation elements to the patient's heart may cause a tamponade condition. In some instances, the controller may be configured to monitor the accelerometer signal of the leadless cardiac pacemaker and determine if a tamponade condition of the patient's heart is indicated based at least in part on the monitored accelerometer signal. If the controller determines that a tamponade condition is indicated, the controller may provide a notification of the tamponade condition for use by a physician to take corrective action.

Additionally, or alternatively, in some embodiments according to the first illustrative embodiment, to determine if a tamponade condition of the patient's heart is indicated based at least in part on the monitored accelerometer signal, the controller may be configured to identify a characteristic of the accelerometer signal, determine if the identified characteristic changes (e.g. diminishes) over time, and determine that the tamponade condition is indicated if the identified

2

characteristic of the of the accelerometer signal changes (e.g. diminishes) over time.

Additionally, or alternatively, in any of the above embodiments according to the first illustrative embodiment, the identified characteristic may comprise a peak amplitude of the accelerometer signal.

Additionally, or alternatively, in any of the above embodiments according to the first illustrative embodiment, the identified characteristic may comprise a peak amplitude of an integral of the accelerometer signal.

Additionally, or alternatively, in any of the above embodiments according to the first illustrative embodiment, determining if the identified characteristic diminishes over time may comprise determining if the identified characteristic falls below a predetermined threshold.

Additionally, or alternatively, in any of the above embodiments according to the first illustrative embodiment, wherein the accelerometer signal may represent one axis of a multi-axis accelerometer.

Additionally, or alternatively, in any of the above embodiments according to the first illustrative embodiment, the accelerometer signal may represent a summed signal of all axes of a multi-axis accelerometer.

Additionally, or alternatively, in any of the above embodiments according to the first illustrative embodiment, to provide the notification, the controller may be configured to communicate a message to an external device programmer.

Additionally, or alternatively, in any of the above embodiments according to the first illustrative embodiment, the notification of the tamponade condition may be communicated using two or more of the plurality of electrodes of the leadless cardiac pacemaker.

Additionally, or alternatively, in any of the above embodiments according to the first illustrative embodiment, to determine if a tamponade condition of the patient's heart is indicated based at least in part on the monitored accelerometer signal, the controller may be configured to determine if a feature of the accelerometer signal falls below a first threshold.

Additionally, or alternatively, in any of the above embodiments according to the first illustrative embodiment, to determine if a tamponade condition of the patient's heart is indicated based at least in part on the monitored accelerometer signal, the controller may be further configured to determine if the feature of the accelerometer signal rises above a second threshold within a predetermined period of time, and determine that the tamponade condition is indicated if the feature of the accelerometer signal does not rise above the second threshold within the predetermined period of time.

Additionally, or alternatively, in any of the above embodiments according to the first illustrative embodiment, to determine if a tamponade condition of the patient's heart is indicated based at least in part on the monitored accelerometer signal, the controller may be further configured to determine whether the feature of the accelerometer signal has diminished below a second threshold value before rising above a third threshold value, and determine that the tamponade condition is indicated if the feature of the accelerometer signal has diminished below the second threshold value before rising above the third threshold value.

Additionally, or alternatively, in any of the above embodiments according to the first illustrative embodiment, the third threshold value may be less than the first threshold value.

Additionally, or alternatively, in any of the above embodiments according to the first illustrative embodiment, the

leadless cardiac pacemaker may further comprise a pressure sensor, and the controller the controller may be further configured to monitor a cardiac electrical signal sensed via the plurality of electrodes, determine if a tamponade condition of the patient's heart is indicated based at least in part on the sensed cardiac electrical signal, and in response to determining that the tamponade condition is indicated, provide a notification of the tamponade condition for use by a physician to take corrective action.

Additionally, or alternatively, in any of the above embodiments according to the first illustrative embodiment, to determine if a tamponade condition of the patient's heart is indicated based at least in part on the intracardiac signal, the controller may be configured to determine if a detected peak amplitude of the intracardiac pressure signal diminishes below a threshold value.

In a second illustrative embodiment, a method for detecting a tamponade condition of a patient's heart after attachment of a leadless cardiac pacemaker to the patient's heart, the leadless cardiac pacemaker having an accelerometer that produces an accelerometer signal, may comprise monitoring the accelerometer signal of the leadless cardiac pacemaker, determining if a tamponade condition of the patient's heart is indicated based at least in part on the monitored accelerometer signal, and in response to determining that the tamponade condition is indicated, providing a notification of the tamponade condition for use by a physician to take corrective action.

Additionally, or alternatively, in any of the above embodiments according to the second illustrative embodiment, the determining step may comprise identifying a characteristic of the accelerometer signal, determining if the identified characteristic diminishes over time, and determining that the tamponade condition is indicated if the identified characteristic of the of the accelerometer signal diminishes over time.

Additionally, or alternatively, in any of the above embodiments according to the second illustrative embodiment, the identified characteristic may comprise a peak amplitude of the accelerometer signal.

Additionally, or alternatively, in any of the above embodiments according to the second illustrative embodiment, the identified characteristic may comprise a peak amplitude of an integral of the accelerometer signal.

Additionally, or alternatively, in any of the above embodiments according to the second illustrative embodiment, the accelerometer signal may represent one axis of a multi-axis accelerometer.

Additionally, or alternatively, in any of the above embodiments according to the second illustrative embodiment, the accelerometer signal may represent a summed signal of all axes of a multi-axis accelerometer.

Additionally, or alternatively, in any of the above embodiments according to the second illustrative embodiment, determining if the identified characteristic diminishes over time may comprise determining if the identified characteristic falls below a predetermined threshold.

Additionally, or alternatively, in any of the above embodiments according to the second illustrative embodiment, the leadless cardiac pacemaker may perform the monitoring, determining and providing steps.

Additionally, or alternatively, in any of the above embodiments according to the second illustrative embodiment, the leadless cardiac pacemaker may perform the monitoring step.

Additionally, or alternatively, in any of the above embodiments according to the second illustrative embodiment, an

external device programmer may perform one or more of the monitoring, determining and providing steps.

Additionally, or alternatively, in any of the above embodiments according to the second illustrative embodiment, providing the notification may comprise communicating a message from the leadless cardiac pacemaker for reception by an external device programmer.

In a third illustrative embodiment, a leadless cardiac pacemaker for use in pacing a patient's heart may comprise a plurality of electrodes, an accelerometer for providing an accelerometer signal, and a controller operatively coupled to the plurality of electrodes and the accelerometer. In at least some embodiments, the controller may be configured to monitor the accelerometer signal of the accelerometer over time, determine if a tamponade condition of the patient's heart is indicated based at least in part on the monitored accelerometer signal, and, in response to determining that the tamponade condition is indicated, communicate a notification of the tamponade condition for use by a physician to take corrective action.

Additionally, or alternatively, in any of the above embodiments according to the third illustrative embodiment, the notification of the tamponade condition may be communicated using two or more of the plurality of electrodes of the leadless cardiac pacemaker.

Additionally, or alternatively, in any of the above embodiments according to the third illustrative embodiment, to determine if the tamponade condition of the patient's heart is indicated, the controller may be configured to identify a characteristic of the accelerometer signal, determine if the identified characteristic diminishes over time, and determine that the tamponade condition is indicated if the identified characteristic of the of the accelerometer signal diminishes over time.

Additionally, or alternatively, in any of the above embodiments according to the third illustrative embodiment, the identified characteristic may comprise a peak amplitude of the accelerometer signal.

Additionally, or alternatively, in any of the above embodiments according to the third illustrative embodiment, the identified characteristic may comprise a peak amplitude of an integral of the accelerometer signal.

In a fourth illustrative embodiment, a leadless cardiac pacemaker may comprise a plurality of electrodes, an accelerometer for providing an accelerometer signal, a controller operatively coupled to the plurality of electrodes and the accelerometer. In at least some embodiments, the controller may be configured to monitor an indication of a range of physical motion of a patient's heart over time using the accelerometer signal, determine if the indication of the range of physical motion of the patient's heart reduces over time by at least a predefined amount, and, if it is determined that the indication of the range of physical motion of the patient's heart has reduced over time by at least the predefined amount, communicate a notification of a possible tamponade condition for reception by a remote device that is remote from the leadless cardiac pacemaker.

Additionally, or alternatively, in any of the above embodiments according to the fourth illustrative embodiment, the controller may be further configured to monitor a heart rate of the patient's heart over time and to determine if the heart rate increases over time by at least a predetermined heart rate amount.

Additionally, or alternatively, in any of the above embodiments according to the fourth illustrative embodiment, the controller may only communicate a notification of the possible tamponade condition if it is determined that the

indication of the range of physical motion of the patient's heart has reduced over time by at least the predefined amount and the heart rate of the patient's heart has increased over time by at least the predetermined heart rate amount.

Additionally, or alternatively, in any of the above embodiments according to the fourth illustrative embodiment, the notification of the possible tamponade condition may be communicated using two or more of the plurality of electrodes of the leadless cardiac pacemaker.

The above summary is not intended to describe each embodiment or every implementation of the present disclosure. Advantages and attainments, together with a more complete understanding of the disclosure, will become apparent and appreciated by referring to the following description and claims taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

The disclosure may be more completely understood in consideration of the following description of various illustrative embodiments in connection with the accompanying drawings, in which:

FIG. 1 is a schematic block diagram of an illustrative leadless cardiac pacemaker (LCP) according to one embodiment of the present disclosure;

FIG. 2 is a schematic block diagram of another illustrative medical device that may be used in conjunction with the LCP of FIG. 1;

FIG. 3 is a schematic diagram of an exemplary medical system that includes multiple LCPs and/or other devices in communication with one another;

FIG. 4 is a schematic diagram of a system including an LCP and another medical device, in accordance with another embodiment of the present disclosure;

FIG. 5 is a graph showing an illustrative cardiac electrical signal and illustrative accelerometer signals detected by an LCP;

FIG. 6 is a graph showing an illustrative cardiac electrical signal and an illustrative accelerometer signal detected by an LCP;

FIG. 7 is a graph showing an illustrative accelerometer signal detected by an LCP showing multiple thresholds, in accordance with techniques of the present disclosure;

FIG. 8 is a graph showing an illustrative accelerometer signal detected by an LCP showing multiple thresholds, in accordance with techniques of the present disclosure; and

FIG. 9 is a graph showing an illustrative accelerometer signal detected by an LCP showing multiple thresholds, in accordance with techniques of the present disclosure.

While the disclosure is amenable to various modifications and alternative forms, specifics thereof have been shown by way of embodiment in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit aspects of the disclosure to the particular illustrative embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.

DESCRIPTION

The following description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The description and the

drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the disclosure.

This disclosure describes systems, devices, and methods for detecting a tamponade condition. Cardiac tamponade is a medical condition characterized by compression of the heart due to an accumulation of fluid in the pericardial sac. When a patient is experiencing cardiac tamponade, the electrical system of the heart may be functioning normally. The heart may still be generating intrinsic electrical signals in a normal rhythm, and the generated signals may propagate throughout the heart in a normal fashion. However, since the heart is being compressed by fluid in the pericardial sac, the heart muscle may not be able to relax from a contracted state, thereby limiting the ability of the heart to sufficiently pump blood.

Specifically in relation to medical devices, tamponade may be caused by attaching a medical device or leads of the medical device to the heart. Generally, a medical device or lead may have a fixation element to securely place the device or lead at a location on or within the heart. During implantation, the fixation element may end up puncturing through the heart wall or an artery or other vessel on the outside of the heart, resulting in a leak of blood between the heart muscle and the pericardial sac. As the leak continues, more blood may seep between the heart muscle and the pericardial sac, resulting in continually decreasing pumping action, potentially resulting in a dangerous situation for the patient. The present disclosure describes devices, systems, and techniques for monitoring one or more signals to determine whether a tamponade condition is occurring.

FIG. 1 is a conceptual schematic block diagram of an exemplary leadless cardiac pacemaker (LCP) that may be implanted on the heart or within a chamber of the heart and may operate to sense physiological signals and parameters and deliver one or more types of electrical stimulation therapy to the heart of the patient. Example electrical stimulation therapy may include bradycardia pacing, rate responsive pacing therapy, cardiac resynchronization therapy (CRT), anti-tachycardia pacing (ATP) therapy and/or the like. As can be seen in FIG. 1, LCP 100 may be a compact device with all components housed within LCP 100 or directly on housing 120. In some instances, LCP 100 may include communication module 102, pulse generator module 104, electrical sensing module 106, mechanical sensing module 108, processing module 110, energy storage module 112, and electrodes 114.

As depicted in FIG. 1, LCP 100 may include electrodes 114, which can be secured relative to housing 120 and electrically exposed to tissue and/or blood surrounding LCP 100. Electrodes 114 may generally conduct electrical signals to and from LCP 100 and the surrounding tissue and/or blood. Such electrical signals can include communication signals, electrical stimulation pulses, and intrinsic cardiac electrical signals, to name a few. Intrinsic cardiac electrical signals may include electrical signals generated by the heart and may be represented by an electrocardiogram (ECG).

Electrodes 114 may include one or more biocompatible conductive materials such as various metals or alloys that are known to be safe for implantation within a human body. In some instances, electrodes 114 may be generally disposed on either end of LCP 100 and may be in electrical communication with one or more of modules 102, 104, 106, 108, and 110. In embodiments where electrodes 114 are secured directly to housing 120, an insulative material may electrically isolate the electrodes 114 from adjacent electrodes, housing 120, and/or other parts of LCP 100. In some

instances, some or all of electrodes **114** may be spaced from housing **120** and connected to housing **120** and/or other components of LCP **100** through connecting wires. In such instances, the electrodes **114** may be placed on a tail (not shown) that extends out away from the housing **120**. As shown in FIG. 1, in some embodiments, LCP **100** may include electrodes **114'**. Electrodes **114'** may be in addition to electrodes **114**, or may replace one or more of electrodes **114**. Electrodes **114'** may be similar to electrodes **114** except that electrodes **114'** are disposed on the sides of LCP **100**. In some cases, electrodes **114'** may increase the number of electrodes by which LCP **100** may deliver communication signals and/or electrical stimulation pulses, and/or may sense intrinsic cardiac electrical signals, communication signals, and/or electrical stimulation pulses.

Electrodes **114** and/or **114'** may assume any of a variety of sizes and/or shapes, and may be spaced at any of a variety of spacings. For example, electrodes **114** may have an outer diameter of two to twenty millimeters (mm). In other embodiments, electrodes **114** and/or **114'** may have a diameter of two, three, five, seven millimeters (mm), or any other suitable diameter, dimension and/or shape. Example lengths for electrodes **114** and/or **114'** may include, for example, one, three, five, ten millimeters (mm), or any other suitable length. As used herein, the length is a dimension of electrodes **114** and/or **114'** that extends away from the outer surface of the housing **120**. In some instances, at least some of electrodes **114** and/or **114'** may be spaced from one another by a distance of twenty, thirty, forty, fifty millimeters (mm), or any other suitable spacing. The electrodes **114** and/or **114'** of a single device may have different sizes with respect to each other, and the spacing and/or lengths of the electrodes on the device may or may not be uniform.

In the embodiment shown, communication module **102** may be electrically coupled to electrodes **114** and/or **114'** and may be configured to deliver communication pulses to tissues of the patient for communicating with other devices such as sensors, programmers, other medical devices, and/or the like. Communication signals, as used herein, may be any modulated signal that conveys information to another device, either by itself or in conjunction with one or more other modulated signals. In some embodiments, communication signals may be limited to sub-threshold signals that do not result in capture of the heart yet still convey information. The communication signals may be delivered to another device that is located either external or internal to the patient's body. In some instances, the communication may take the form of distinct communication pulses separated by various amounts of time. In some of these cases, the timing between successive pulses may convey information. Communication module **102** may additionally be configured to sense for communication signals delivered by other devices, which may be located external or internal to the patient's body.

Communication module **102** may communicate to help accomplish one or more desired functions. Some example functions include delivering sensed data, using communicated data for determining occurrences of events such as arrhythmias, coordinating delivery of electrical stimulation therapy, and/or other functions. In some cases, LCP **100** may use communication signals to communicate raw information, processed information, messages and/or commands, and/or other data. Raw information may include information such as sensed electrical signals (e.g. a sensed ECG), signals gathered from coupled sensors, and the like. In some embodiments, the processed information may include signals that have been filtered using one or more signal pro-

cessing techniques. Processed information may also include parameters and/or events that are determined by the LCP **100** and/or another device, such as a determined heart rate, timing of determined heartbeats, timing of other determined events, determinations of threshold crossings, expirations of monitored time periods, accelerometer signals, activity level parameters, blood-oxygen parameters, blood pressure parameters, heart sound parameters, and the like. Messages and/or commands may include instructions or the like directing another device to take action, notifications of imminent actions of the sending device, requests for reading from the receiving device, requests for writing data to the receiving device, information messages, and/or other messages commands.

In at least some embodiments, communication module **102** (or LCP **100**) may further include switching circuitry to selectively connect one or more of electrodes **114** and/or **114'** to communication module **102** in order to select which electrodes **114** and/or **114'** that communication module **102** delivers communication pulses. It is contemplated that communication module **102** may be communicating with other devices via conducted signals, radio frequency (RF) signals, optical signals, acoustic signals, inductive coupling, and/or any other suitable communication methodology. Where communication module **102** generates electrical communication signals, communication module **102** may include one or more capacitor elements and/or other charge storage devices to aid in generating and delivering communication signals. In the embodiment shown, communication module **102** may use energy stored in energy storage module **112** to generate the communication signals. In at least some examples, communication module **102** may include a switching circuit that is connected to energy storage module **112** and, with the switching circuitry, may connect energy storage module **112** to one or more of electrodes **114/114'** to generate the communication signals.

As shown in FIG. 1, a pulse generator module **104** may be electrically connected to one or more of electrodes **114** and/or **114'**. Pulse generator module **104** may be configured to generate electrical stimulation pulses and deliver the electrical stimulation pulses to tissues of a patient via one or more of the electrodes **114** and/or **114'** in order to effectuate one or more electrical stimulation therapies. Electrical stimulation pulses as used herein are meant to encompass any electrical signals that may be delivered to tissue of a patient for purposes of treatment of any type of disease or abnormality. For example, when used to treat heart disease, the pulse generator module **104** may generate electrical stimulation pacing pulses for capturing the heart of the patient, i.e. causing the heart to contract in response to the delivered electrical stimulation pulse. In some of these cases, LCP **100** may vary the rate at which pulse generator **104** generates the electrical stimulation pulses, for example in rate adaptive pacing. In other embodiments, the electrical stimulation pulses may include defibrillation/cardioversion pulses for shocking the heart out of fibrillation or into a normal heart rhythm. In yet other embodiments, the electrical stimulation pulses may include anti-tachycardia pacing (ATP) pulses. It should be understood that these are just some examples. When used to treat other ailments, the pulse generator module **104** may generate electrical stimulation pulses suitable for neurostimulation therapy or the like. Pulse generator module **104** may include one or more capacitor elements and/or other charge storage devices to aid in generating and delivering appropriate electrical stimulation pulses. In at least some embodiments, pulse generator module **104** may use energy stored in energy storage module

112 to generate the electrical stimulation pulses. In some particular embodiments, pulse generator module 104 may include a switching circuit that is connected to energy storage module 112 and may connect energy storage module 112 to one or more of electrodes 114/114' to generate electrical stimulation pulses.

LCP 100 may further include an electrical sensing module 106 and mechanical sensing module 108. Electrical sensing module 106 may be configured to sense intrinsic cardiac electrical signals conducted from electrodes 114 and/or 114' to electrical sensing module 106. For example, electrical sensing module 106 may be electrically connected to one or more electrodes 114 and/or 114' and electrical sensing module 106 may be configured to receive cardiac electrical signals conducted through electrodes 114 and/or 114' via a sensor amplifier or the like. In some embodiments, the cardiac electrical signals may represent local information from the chamber in which LCP 100 is implanted. For instance, if LCP 100 is implanted within a ventricle of the heart, cardiac electrical signals sensed by LCP 100 through electrodes 114 and/or 114' may represent ventricular cardiac electrical signals. Mechanical sensing module 108 may include, or be electrically connected to, various sensors, such as accelerometers, including multi-axis accelerometers such as two- or three-axis accelerometers, gyroscopes, including multi-axis gyroscopes such as two- or three-axis gyroscopes, blood pressure sensors, heart sound sensors, piezoelectric sensors, blood-oxygen sensors, and/or other sensors which measure one or more physiological parameters of the heart and/or patient. Mechanical sensing module 108, when present, may gather signals from the sensors indicative of the various physiological parameters. Both electrical sensing module 106 and mechanical sensing module 108 may be connected to processing module 110 and may provide signals representative of the sensed cardiac electrical signals and/or physiological signals to processing module 110. Although described with respect to FIG. 1 as separate sensing modules, in some embodiments, electrical sensing module 106 and mechanical sensing module 108 may be combined into a single module. In at least some examples, LCP 100 may only include one of electrical sensing module 106 and mechanical sensing module 108. In some cases, any combination of the processing module 110, electrical sensing module 106, mechanical sensing module 108, communication module 102, pulse generator module 104 and/or energy storage module may be considered a controller of the LCP 100.

Processing module 110 may be configured to direct the operation of LCP 100 and may, in some embodiments, be termed a controller. For example, processing module 110 may be configured to receive cardiac electrical signals from electrical sensing module 106 and/or physiological signals from mechanical sensing module 108. Based on the received signals, processing module 110 may determine, for example, occurrences and types of arrhythmias and other determinations such as whether LCP 100 has become dislodged. Processing module 110 may further receive information from communication module 102. In some embodiments, processing module 110 may additionally use such received information to determine occurrences and types of arrhythmias and/or other determinations such as whether LCP 100 has become dislodged. In still some additional embodiments, LCP 100 may use the received information instead of the signals received from electrical sensing module 106 and/or mechanical sensing module 108—for instance if the received information is deemed to be more accurate than the signals received from electrical sensing module 106 and/or

mechanical sensing module 108 or if electrical sensing module 106 and/or mechanical sensing module 108 have been disabled or omitted from LCP 100.

After determining an occurrence of an arrhythmia, processing module 110 may control pulse generator module 104 to generate electrical stimulation pulses in accordance with one or more electrical stimulation therapies to treat the determined arrhythmia. For example, processing module 110 may control pulse generator module 104 to generate pacing pulses with varying parameters and in different sequences to effectuate one or more electrical stimulation therapies. As one example, in controlling pulse generator module 104 to deliver bradycardia pacing therapy, processing module 110 may control pulse generator module 104 to deliver pacing pulses designed to capture the heart of the patient at a regular interval to help prevent the heart of a patient from falling below a predetermined threshold. In some cases, the rate of pacing may be increased with an increased activity level of the patient (e.g. rate adaptive pacing). For instance, processing module 110 may monitor one or more physiological parameters of the patient which may indicate a need for an increased heart rate (e.g. due to increased metabolic demand). Processing module 110 may then increase the rate at which pulse generator 104 generates electrical stimulation pulses.

For ATP therapy, processing module 110 may control pulse generator module 104 to deliver pacing pulses at a rate faster than an intrinsic heart rate of a patient in attempt to force the heart to beat in response to the delivered pacing pulses rather than in response to intrinsic cardiac electrical signals. Once the heart is following the pacing pulses, processing module 110 may control pulse generator module 104 to reduce the rate of delivered pacing pulses down to a safer level. In CRT, processing module 110 may control pulse generator module 104 to deliver pacing pulses in coordination with another device to cause the heart to contract more efficiently. In cases where pulse generator module 104 is capable of generating defibrillation and/or cardioversion pulses for defibrillation/cardioversion therapy, processing module 110 may control pulse generator module 104 to generate such defibrillation and/or cardioversion pulses. In some cases, processing module 110 may control pulse generator module 104 to generate electrical stimulation pulses to provide electrical stimulation therapies different than those examples described above.

Aside from controlling pulse generator module 104 to generate different types of electrical stimulation pulses and in different sequences, in some embodiments, processing module 110 may also control pulse generator module 104 to generate the various electrical stimulation pulses with varying pulse parameters. For example, each electrical stimulation pulse may have a pulse width and a pulse amplitude. Processing module 110 may control pulse generator module 104 to generate the various electrical stimulation pulses with specific pulse widths and pulse amplitudes. For example, processing module 110 may cause pulse generator module 104 to adjust the pulse width and/or the pulse amplitude of electrical stimulation pulses if the electrical stimulation pulses are not effectively capturing the heart. Such control of the specific parameters of the various electrical stimulation pulses may help LCP 100 provide more effective delivery of electrical stimulation therapy.

In some embodiments, processing module 110 may further control communication module 102 to send information to other devices. For example, processing module 110 may control communication module 102 to generate one or more communication signals for communicating with other

11

devices of a system of devices. For instance, processing module **110** may control communication module **102** to generate communication signals in particular pulse sequences, where the specific sequences convey different information. Communication module **102** may also receive communication signals for potential action by processing module **110**.

In further embodiments, processing module **110** may control switching circuitry by which communication module **102** and pulse generator module **104** deliver communication signals and/or electrical stimulation pulses to tissue of the patient. As described above, both communication module **102** and pulse generator module **104** may include circuitry for connecting one or more electrodes **114** and **114'** to communication module **102** and/or pulse generator module **104** so those modules may deliver the communication signals and electrical stimulation pulses to tissue of the patient. The specific combination of one or more electrodes by which communication module **102** and/or pulse generator module **104** deliver communication signals and electrical stimulation pulses may influence the reception of communication signals and/or the effectiveness of electrical stimulation pulses. Although it was described that each of communication module **102** and pulse generator module **104** may include switching circuitry, in some embodiments, LCP **100** may have a single switching module connected to the communication module **102**, the pulse generator module **104**, and electrodes **114** and/or **114'**. In such embodiments, processing module **110** may control the switching module to connect modules **102/104** and electrodes **114/114'** as appropriate.

In some embodiments, processing module **110** may include a pre-programmed chip, such as a very-large-scale integration (VLSI) chip or an application specific integrated circuit (ASIC). In such embodiments, the chip may be pre-programmed with control logic in order to control the operation of LCP **100**. By using a pre-programmed chip, processing module **110** may use less power than other programmable circuits while able to maintain basic functionality, thereby potentially increasing the battery life of LCP **100**. In other instances, processing module **110** may include a programmable microprocessor or the like. Such a programmable microprocessor may allow a user to adjust the control logic of LCP **100** after manufacture, thereby allowing for greater flexibility of LCP **100** than when using a pre-programmed chip. In still other embodiments, processing module **110** may not be a single component. For example, processing module **110** may include multiple components positioned at disparate locations within LCP **100** in order to perform the various described functions. For example, certain functions may be performed in one component of processing module **110**, while other functions are performed in a separate component of processing module **110**.

Processing module **110**, in additional embodiments, may include a memory circuit and processing module **110** may store information on and read information from the memory circuit. In other embodiments, LCP **100** may include a separate memory circuit (not shown) that is in communication with processing module **110**, such that processing module **110** may read and write information to and from the separate memory circuit. The memory circuit, whether part of processing module **110** or separate from processing module **110**, may be volatile memory, non-volatile memory, or a combination of volatile memory and non-volatile memory.

12

Energy storage module **112** may provide a power source to LCP **100** for its operations. In some embodiments, energy storage module **112** may be a non-rechargeable lithium-based battery. In other embodiments, the non-rechargeable battery may be made from other suitable materials. In some embodiments, energy storage module **112** may include a rechargeable battery. In still other embodiments, energy storage module **112** may include other types of energy storage devices such as capacitors or super capacitors.

To implant LCP **100** inside a patient's body, an operator (e.g., a physician, clinician, etc.), may fix LCP **100** to the cardiac tissue of the patient's heart. To facilitate fixation, LCP **100** may include one or more anchors **116**. The one or more anchors **116** are shown schematically in FIG. **1**. The one or more anchors **116** may include any number of fixation or anchoring mechanisms. For example, one or more anchors **116** may include one or more pins, staples, threads, screws, helix, tines, and/or the like. In some embodiments, although not shown, one or more anchors **116** may include threads on its external surface that may run along at least a partial length of an anchor member. The threads may provide friction between the cardiac tissue and the anchor to help fix the anchor member within the cardiac tissue. In some cases, the one or more anchors **116** may include an anchor member that has a cork-screw shape that can be screwed into the cardiac tissue. In other embodiments, anchor **116** may include other structures such as barbs, spikes, or the like to facilitate engagement with the surrounding cardiac tissue.

In some examples, LCP **100** may be configured to be implanted on a patient's heart or within a chamber of the patient's heart. For instance, LCP **100** may be implanted within any of a left atrium, right atrium, left ventricle, or right ventricle of a patient's heart. By being implanted within a specific chamber, LCP **100** may be able to sense cardiac electrical signals originating or emanating from the specific chamber that other devices may not be able to sense with such resolution. Where LCP **100** is configured to be implanted on a patient's heart, LCP **100** may be configured to be implanted on or adjacent to one of the chambers of the heart, or on or adjacent to a path along which intrinsically generated cardiac electrical signals generally follow. In these examples, LCP **100** may also have an enhanced ability to sense localized intrinsic cardiac electrical signals and deliver localized electrical stimulation therapy.

FIG. **2** depicts an embodiment of another device, medical device (MD) **200**, which may operate to sense physiological signals and parameters and deliver one or more types of electrical stimulation therapy to tissues of the patient. In the embodiment shown, MD **200** may include a communication module **202**, a pulse generator module **204**, an electrical sensing module **206**, a mechanical sensing module **208**, a processing module **210**, and an energy storage module **218**. Each of modules **202**, **204**, **206**, **208**, and **210** may be similar to modules **102**, **104**, **106**, **108**, and **110** of LCP **100**. Additionally, energy storage module **218** may be similar to energy storage module **112** of LCP **100**. However, in some embodiments, MD **200** may have a larger volume within housing **220**. In such embodiments, MD **200** may include a larger energy storage module **218** and/or a larger processing module **210** capable of handling more complex operations than processing module **110** of LCP **100**.

While MD **200** may be another leadless device such as shown in FIG. **1**, in some instances MD **200** may include leads, such as leads **212**. Leads **212** may include electrical wires that conduct electrical signals between electrodes **214** and one or more modules located within housing **220**. In

some cases, leads **212** may be connected to and extend away from housing **220** of MD **200**. In some embodiments, leads **212** are implanted on, within, or adjacent to a heart of a patient. Leads **212** may contain one or more electrodes **214** positioned at various locations on leads **212** and various distances from housing **220**. Some leads **212** may only include a single electrode **214**, while other leads **212** may include multiple electrodes **214**. Generally, electrodes **214** are positioned on leads **212** such that when leads **212** are implanted within the patient, one or more of the electrodes **214** are positioned to perform a desired function. In some cases, the one or more of the electrodes **214** may be in contact with the patient's cardiac tissue. In other cases, the one or more of the electrodes **214** may be positioned subcutaneously but adjacent the patient's heart. The electrodes **214** may conduct intrinsically generated electrical cardiac signals to leads **212**. Leads **212** may, in turn, conduct the received electrical cardiac signals to one or more of the modules **202**, **204**, **206**, and **208** of MD **200**. In some cases, MD **200** may generate electrical stimulation signals, and leads **212** may conduct the generated electrical stimulation signals to electrodes **214**. Electrodes **214** may then conduct the electrical stimulation signals to the cardiac tissue of the patient (either directly or indirectly). MD **200** may also include one or more electrodes **214** not disposed on a lead **212**. For example, one or more electrodes **214** may be connected directly to housing **220**.

Leads **212**, in some embodiments, may additionally contain one or more sensors, such as accelerometers, blood pressure sensors, heart sound sensors, blood-oxygen sensors, and/or other sensors which are configured to measure one or more physiological parameters of the heart and/or patient. In such embodiments, mechanical sensing module **208** may be in electrical communication with leads **212** and may receive signals generated from such sensors.

While not required, in some embodiments MD **200** may be an implantable medical device. In such embodiments, housing **220** of MD **200** may be implanted in, for example, a transthoracic region of the patient. Housing **220** may generally include any of a number of known materials that are safe for implantation in a human body and may, when implanted, hermetically seal the various components of MD **200** from fluids and tissues of the patient's body. In such embodiments, leads **212** may be implanted at one or more various locations within the patient, such as within the heart of the patient, adjacent to the heart of the patient, adjacent to the spine of the patient, or any other desired location.

In some embodiments, MD **200** may be an implantable cardiac pacemaker (ICP). In these embodiments, MD **200** may have one or more leads, for example leads **212**, which are implanted on or within the patient's heart. The one or more leads **212** may include one or more electrodes **214** that are in contact with cardiac tissue and/or blood of the patient's heart. MD **200** may be configured to sense intrinsically generated cardiac electrical signals and determine, for example, one or more cardiac arrhythmias based on analysis of the sensed signals. MD **200** may be configured to deliver CRT, ATP therapy, bradycardia therapy, and/or other therapy types via leads **212** implanted within the heart. In some embodiments, MD **200** may additionally be configured to provide defibrillation/cardioversion therapy.

In some instances, MD **200** may be an implantable cardioverter-defibrillator (ICD). In such embodiments, MD **200** may include one or more leads implanted within a patient's heart. MD **200** may also be configured to sense electrical cardiac signals, determine occurrences of tachyarrhythmias based on the sensed electrical cardiac signals, and

deliver defibrillation and/or cardioversion therapy in response to determining an occurrence of a tachyarrhythmia (for example by delivering defibrillation and/or cardioversion pulses to the heart of the patient). In other embodiments, MD **200** may be a subcutaneous implantable cardioverter-defibrillator (SICD). In embodiments where MD **200** is an SICD, one of leads **212** may be a subcutaneously implanted lead. In at least some embodiments where MD **200** is an SICD, MD **200** may include only a single lead which is implanted subcutaneously but outside of the chest cavity, however this is not required.

In some embodiments, MD **200** may not be an implantable medical device. Rather, MD **200** may be a device external to the patient's body, and electrodes **214** may be skin-electrodes that are placed on a patient's body. In such embodiments, MD **200** may be able to sense surface electrical signals (e.g. electrical cardiac signals that are generated by the heart or electrical signals generated by a device implanted within a patient's body and conducted through the body to the skin). MD **200** may further be configured to deliver various types of electrical stimulation therapy, including, for example, defibrillation therapy via skin-electrodes **214**.

FIG. 3 illustrates an embodiment of a medical device system and a communication pathway through which multiple medical devices **302**, **304**, **306**, and/or **310** of the medical device system may communicate. In the embodiment shown, medical device system **300** may include LCPs **302** and **304**, external medical device **306**, and other sensors/devices **310**. External device **306** may be a device disposed external to a patient's body, as described previously with respect to MD **200**. In at least some examples, external device **306** may represent an external support device such as a device programmer, as will be described in more detail below. Other sensors/devices **310** may be any of the devices described previously with respect to MD **200**, such as ICPs, ICDs, and SICDs. Other sensors/devices **310** may also include various diagnostic sensors that gather information about the patient, such as accelerometers, blood pressure sensors, or the like. In some cases, other sensors/devices **310** may include an external programmer device that may be used to program one or more devices of system **300**.

Various devices of system **300** may communicate via communication pathway **308**. For example, LCPs **302** and/or **304** may sense intrinsic cardiac electrical signals and may communicate such signals to one or more other devices **302/304**, **306**, and **310** of system **300** via communication pathway **308**. In one embodiment, one or more of devices **302/304** may receive such signals and, based on the received signals, determine an occurrence of an arrhythmia. In some cases, device or devices **302/304** may communicate such determinations to one or more other devices **306** and **310** of system **300**. In some cases, one or more of devices **302/304**, **306**, and **310** of system **300** may take action based on the communicated determination of an arrhythmia, such as by delivering a suitable electrical stimulation to the heart of the patient. One or more of devices **302/304**, **306**, and **310** of system **300** may additionally communicate command or response messages via communication pathway **308**. The command messages may cause a receiving device to take a particular action whereas response messages may include requested information or a confirmation that a receiving device did, in fact, receive a communicated message or data.

It is contemplated that the various devices of system **300** may communicate via pathway **308** using RF signals, inductive coupling, optical signals, acoustic signals, or any other signals suitable for communication. Additionally, in at least

some embodiments, the various devices of system 300 may communicate via pathway 308 using multiple signal types. For instance, other sensors/device 310 may communicate with external device 306 using a first signal type (e.g. RF communication) but communicate with LCPs 302/304 using a second signal type (e.g. conducted communication). Further, in some embodiments, communication between devices may be limited. For instance, as described above, in some embodiments, LCPs 302/304 may communicate with external device 306 only through other sensors/devices 310, where LCPs 302/304 send signals to other sensors/devices 310, and other sensors/devices 310 relay the received signals to external device 306.

In some cases, the various devices of system 300 may communicate via pathway 308 using conducted communication signals. Accordingly, devices of system 300 may have components that allow for such conducted communication. For instance, the devices of system 300 may be configured to transmit conducted communication signals (e.g. a voltage and/or current waveform punctuated with current and/or voltage pulses, referred herein as electrical communication pulses) into the patient's body via one or more electrodes of a transmitting device, and may receive the conducted communication signals via one or more electrodes of a receiving device. The patient's body may "conduct" the conducted communication signals from the one or more electrodes of the transmitting device to the electrodes of the receiving device in the system 300. In such embodiments, the delivered conducted communication signals may differ from pacing pulses, defibrillation and/or cardioversion pulses, or other electrical stimulation therapy signals. For example, the devices of system 300 may deliver electrical communication pulses at an amplitude/pulse width that is sub-threshold. That is, the communication pulses have an amplitude/pulse width designed to not capture the heart. In some cases, the amplitude/pulse width of the delivered electrical communication pulses may be above the capture threshold of the heart, but may be delivered during a refractory period of the heart and/or may be incorporated in or modulated onto a pacing pulse, if desired.

Additionally, unlike normal electrical stimulation therapy pulses, the electrical communication pulses may be delivered in specific sequences which convey information to receiving devices. For instance, delivered electrical communication pulses may be modulated in any suitable manner to encode communicated information. In some cases, the communication pulses may be pulse width modulated and/or amplitude modulated. Alternatively, or in addition, the time between pulses may be modulated to encode desired information. In some cases, a predefined sequence of communication pulses may represent a corresponding symbol (e.g. a logic "1" symbol, a logic "0" symbol, an ATP therapy trigger symbol, etc.). In some cases, conducted communication pulses may be voltage pulses, current pulses, biphasic voltage pulses, biphasic current pulses, or any other suitable electrical pulse as desired.

FIG. 4 depicts an illustrative medical device system 400 that may be configured to operate together. For example, system 400 may include multiple devices that are implanted within a patient and are configured to sense physiological signals, determine occurrences of cardiac arrhythmias, and deliver electrical stimulation to treat detected cardiac arrhythmias. In some embodiments, the devices of system 400 may be configured to determine occurrences of dislodgment of one or more devices of system 400. In FIG. 4, an LCP 402 is shown fixed to the interior of the right ventricle of the heart 410, and a pulse generator 406 is shown coupled

to a lead 412 having one or more electrodes 408a-408c. In some cases, pulse generator 406 may be part of a subcutaneous implantable cardioverter-defibrillator (SICD), and the one or more electrodes 408a-408c may be positioned subcutaneously adjacent the heart. LCP 402 may communicate with the SICD, such as via communication pathway 308. The locations of LCP 402, pulse generator 406, lead 412, and electrodes 408a-c depicted in FIG. 4 are just exemplary. In other embodiments of system 400, LCP 402 may be positioned in the left ventricle, right atrium, or left atrium of the heart, as desired. In still other embodiments, LCP 402 may be implanted externally adjacent to heart 410 or even remote from heart 410.

Medical device system 400 may also include external support device 420. External support device 420 can be used to perform functions such as device identification, device programming and/or transfer of real-time and/or stored data between devices using one or more of the communication techniques described herein, or other functions involving communication with one or more devices of system 400. As one example, communication between external support device 420 and pulse generator 406 can be performed via a wireless mode, and communication between pulse generator 406 and LCP 402 can be performed via a conducted communication mode. In some embodiments, communication between LCP 402 and external support device 420 is accomplished by sending communication information through pulse generator 406. However, in other embodiments, communication between the LCP 402 and external support device 420 may be via a communication module.

FIG. 4 only illustrates one example embodiment of a medical device system that may be configured to operate according to techniques disclosed herein. Other example medical device systems may include additional or different medical devices and/or configurations. For instance, other medical device systems that are suitable to operate according to techniques disclosed herein may include additional LCPs implanted within the heart. Another example medical device system may include a plurality of LCPs with or without other devices such as pulse generator 406, with at least one LCP capable of delivering defibrillation therapy. Still another example may include one or more LCPs implanted along with a transvenous pacemaker and with or without an implanted SICD. In yet other embodiments, the configuration or placement of the medical devices, leads, and/or electrodes may be different from those depicted in FIG. 4. Accordingly, it should be recognized that numerous other medical device systems, different from system 400 depicted in FIG. 4, may be operated in accordance with techniques disclosed herein. As such, the embodiment shown in FIG. 4 should not be viewed as limiting in any way.

In some embodiments, LCP 100 may be configured to determine whether a tamponade condition is occurring. For instance, LCP 100 may be configured to monitor one or more signals and determine, based on the one or more monitored signals, whether a tamponade condition is occurring within the heart. Additionally, or alternatively, LCP 100 may use one or more determined features or characteristics of the monitored signal or signals and determine whether tamponade is occurring based on the one or more determined features. In some embodiments, to determine whether a tamponade condition is occurring, LCP 100 may monitor a signal or a feature of the signal and determine whether the signal or the feature changes (e.g. diminishes) over time. Generally, diminishment of a signal or feature over time, such as diminishing below a threshold, may indicate that a tamponade condition is occurring. The below described

techniques illustrate various signals and features that LCP 100 may monitor in order to determine whether a tamponade condition is occurring. In some cases, the LCP 100 may monitor one or more signals or features, and communicate information related to the one or more signals or features to a separate device. In some cases, the actual determination of whether a tamponade condition is occurring may be performed by the separate device.

In some embodiments, LCP 100 may be triggered to enter or exit a tamponade mode, where LCP 100 monitors for whether a tamponade condition is occurring. In some cases, the LCP may enter or exit the tamponade mode based on a communicated trigger signal. LCP 100 may receive such a trigger signal from a device external to LCP 100, such as support device 420, or may be internally generated. Generally, a user may trigger LCP 100, e.g. via external support device 420, to enter the tamponade mode at the time of implant and maintain LCP 100 in the tamponade mode throughout the implantation procedure and for a short time thereafter. A user may additionally trigger LCP 100 to enter the tamponade mode during follow-up procedures or appointments where the physician may be concerned that tamponade is a risk. Outside of these times, the physician may trigger tamponade detection off to save energy in the LCP.

FIG. 5 is a graph 500 showing an illustrative cardiac electrical signal 502 (e.g. ECG) along with corresponding accelerometer signals 504, 506, 508 and 510 of a three axis accelerometer along a common time axis. The signal tracings of graph 500 may represent signals sensed or generated by an LCP 100 when LCP 100 is attached to a wall of a patient's heart. For example, signal 502 may represent a cardiac electrical signal 502 sensed by LCP 100. Signals 504, 506, and 508 may represent signals from different axes generated by a three-axis accelerometer of LCP 100. Signal 510 may represent an accelerometer magnitude signal, which may be determined by summing signals 504, 506, and 508 or summing the absolute values of signals 504, 506, and 508. In other embodiments, signal 510 may represent a different signal generated by other combinations of signals 504, 506, and 508, such as a root-mean-square or root-sum-square of signals 504, 506, and 508, or any other derivation of signals 504, 506, and 508.

LCP 100 may be configured to sense one or more of signals 504, 506, 508 and/or 510 during certain time periods. For instance, to "sense" one or more of the signals, it is contemplated that the LCP 100 may be configured to receive and process signals 504, 506, 508 and/or 510 at processing module 110. Whereas when the one or more of the signals are not being "sensed", processing module 110 of LCP 100 may not receive and/or process the signals 504, 506, 508 and/or 510. In some embodiments, to "sense" signals 504, 506, 508 and/or 510, LCP 100 may connect an output of the accelerometer to processing module 110 via a switch, multiplexer of the like. In other embodiments, the accelerometer may be configured to only output valid signals 504, 506, 508 and/or 510 when the accelerometer is to be sensed (e.g. the accelerometer may be enabled by processing module 110 when sensing is desired). In some cases, LCP 100 may control the generation of signals 504, 506, 508 and/or 510 by the accelerometer. For instance, LCP 100 may control when power is provided to the accelerometer, and the accelerometer may only generate signals 504, 506, 508 and/or 510 when power is provided to the accelerometer. In some cases, LCP 100 may switch the accelerometer from a lower-power state (e.g. a sleep mode) to a higher-power state (e.g. awake or active mode) during time periods where LCP 100 is to

sense the accelerometer signal(s). During the lower-power state, the accelerometer may not provide an appreciable signal for LCP 100 to sense and/or sample. In some cases, and where processing module 110 is a digital device, an A/D converter may sample signals 504, 506, 508 and/or 510 when sensing is desired. These are just some examples of how signals 504, 506, 508 and/or 510 may be "sensed" during certain time periods.

LCP 100 may be configured to sense one or more signals during predetermined time periods. Such predetermined time periods may be represented by sensing periods 512a-512d in FIG. 5. Sensing periods 512a-512d may occur at regular intervals, such as every five seconds, every second, every eight hundred milliseconds, every seven hundred milliseconds, or any other suitable value. Alternatively, LCP 100 may initiate sensing periods 512a-512d after every beat, once every other beat, once every five beats, or at any other suitable frequency and/or duration. In at least some cases, LCP 100 may adjust the interval according to a heart rate of the patient such that successive sensing periods 512a-512d occur during the same portion of the cardiac cycle (e.g. when the heart is quiet such as between heart beats).

In some instances, LCP 100 may implement sensing periods 512a-512d based on one or more detected features of cardiac electrical signal 502. For instance, LCP 100 may detect one or more features of cardiac electrical signal 502, such as cardiac electrical events 511. Cardiac electrical events 511 may represent R-waves or other morphological features detected by LCP 100. Upon detection of cardiac electrical event 511, LCP 100 may initiate a time delay, such as time delay 514. Upon expiration of time delay 514, LCP 100 may initiate sensing periods 512a-512d, during which LCP 100 may "sense" one or more signals, such as signals 504, 506, 508 and/or 510. In at least some cases, LCP 100 may adjust time delay 514 based on the heart rate of the patient. For instance, when the heart rate is at a relatively higher heart rate, LCP 100 may shorten time delay 514, and when the heart rate is at a relatively lower heart rate, LCP 100 may lengthen time delay 514. This may help the LCP 100 consistently initiate sensing periods 512a-512d during the same or similar portion of the cardiac cycle (e.g. during the quiet period between polarization/repolarizations of the heart).

In some instances, the length of time delay 514 may be chosen to align with a portion of the cardiac cycle where the heart is relatively mechanically inactive, such as shown in FIG. 5. For instance, time delay 514 may be chosen so that it expires between about fifty milliseconds to about one-hundred fifty milliseconds before the beginning of the next heartbeat. During this portion of the cardiac cycle, the heart muscle may be in a relatively relaxed state while filling with blood. Accordingly, during this portion of the cardiac cycle, the orientation of LCP 100 may be at a relatively consistent position. This may allow LCP 100 to more easily detect a current posture of the patient, as explained in more detail below. In other embodiments, an accelerometer or other sensor may be implanted in the patient outside of the heart, and may transmit an indication of posture to the LCP 100.

The signals depicted in FIG. 5 may represent signals acquired during normal cardiac function, e.g. when no tamponade condition is occurring. Notice that each of the accelerometer signals following each cardiac electrical event 511 are similar in shape and magnitude.

FIG. 6 depicts graph 520 including an example cardiac electrical signal 522, including cardiac electrical events 531, and accelerometer signal 524 which represents a magnitude of the accelerometer of LCP 100, similar to signal 510 of

FIG. 5. Graph 520 depicts signals 522 and 524 over multiple cardiac cycles where the patient is suffering from a tamponade condition. As can be seen in FIG. 6, the maximum amplitude of signal 524 diminishes over time throughout successive cardiac cycles. However, the maximum amplitude of the illustrative cardiac electrical signal 522 remains relatively constant over the same cardiac cycles. Accordingly, detecting a tamponade condition may be difficult using only the cardiac electrical signal.

While FIG. 6 shows the maximum amplitude of signal 524 diminish rapidly over only five (5) cardiac cycles, this has been intentionally compressed in time for ease of description only. In most cases, the maximum amplitude of signal 524 will diminish much more slowly, such as over minutes, hours or even days. FIGS. 7-9 have been similarly compressed in time for ease of description.

When LCP 100 is in the tamponade mode, LCP 100 may adjust how LCP 100 senses the accelerometer signal(s). As can be seen, time delay 526 of FIG. 6 is relatively shorter than time delay 514 of FIG. 5. The length of time delay 526 may be chosen to generally align with the contraction of the heart. This may help LCP 100 sense the accelerometer signals during sensing periods 523a-e that correspond to when the heart is actually contracting.

In some instances, time delay 526 may be about ten milliseconds, about fifteen milliseconds, about twenty milliseconds, about twenty-five milliseconds, about thirty milliseconds, about thirty-five milliseconds, or any other suitable period of time following a detected R-wave. In general, time delay 526 may have a value that is less than an electromechanical delay of the heart, which is the delay between when LCP 100 detects a cardiac electrical event 531 (e.g. R-wave) and an onset of cardiac wall motion or a threshold amount of cardiac wall motion. Sensing periods 523a-e may have a duration of about twenty-five milliseconds, about thirty milliseconds, about forty milliseconds, or about fifty milliseconds. However, in other embodiments, sensing periods 523a-e may be substantially longer, for instance, about half of a cardiac cycle of the patient, about three quarters of the cardiac cycle of the patient, or may span an entire cardiac cycle of the patient. In some additional or alternative embodiments, time delay 526 and/or sensing periods 523a-e may have lengths that change along with the heart rate of the patient. As one example, for relatively higher heart rates, time delay 526 and/or sensing periods 523a-e may be shorter than for relatively lower heart rates.

In general, LCP 100 may be able to use accelerometer signals sensed during a portion of the cardiac cycle that corresponds to sensing periods 523a-e to determine whether a tamponade condition is occurring. As mentioned previously, when tamponade is occurring, blood or other fluid may be pooling in the pericardial sac, preventing full relaxation of the heart between contractions. The pooled blood may then prevent the heart from contracting to as great of an extent as under normal conditions. This difference in the motion of the heart may be seen through the sensed accelerometer signals.

To determine whether a tamponade condition is occurring, in some instances, LCP 100 may compare a maximum amplitude of signal 524 within a sensing window to a threshold, such as threshold 525. If LCP 100 determines that the maximum amplitude of signal 524 is less than threshold 525, LCP 100 may determine that a tamponade condition is occurring. In other embodiments, after determining that the maximum amplitude of signal 524 is less than threshold 525 in a first sensing window, such as sensing window 523c, LCP 100 may continue to monitor signal 524 during sub-

sequent sensing windows, for example sensing windows 523d and 523e, and comparing signal 524 to threshold 525 during those subsequent sensing windows. In these embodiments, LCP 100 may only determine that a tamponade condition is occurring if the maximum amplitude of signal 524 in a second, subsequent sensing window is also less than threshold 525. In still further embodiments, LCP 100 may require the maximum amplitude of signal 524 to be less than threshold 525 in three (or more) consecutive sensing windows before determining that a tamponade condition is occurring.

In still other embodiments, LCP 100 may require the maximum amplitude of signal 524 to be less than threshold 525 in four, five, ten, or twenty consecutive sensing windows, or any other suitable number of sensing windows, before determining that a tamponade condition is occurring. Other options further include LCP 100 requiring that the maximum amplitude of signal 524 to be less than threshold 525 in three out of five consecutive sensing windows, five out of ten consecutive sensing windows, or any other suitable combinations before determining that a tamponade condition is occurring.

In even more additional or alternative embodiments, after LCP 100 determines the maximum amplitude of signal 524 is less than threshold 525, LCP 100 may track a period of time. LCP 100 may then determine that a tamponade condition is occurring if the maximum amplitude of signal 524 does not cross back above threshold 525 within the pre-defined period of time. In some instances, LCP 100 may switch to continuously or substantially continuously sensing signal 524 (e.g. turn on and/or sample accelerometer signal continuously or substantially continuously). In other embodiments, however, LCP 100 may maintain sensing signal 524 only in sensing windows. Accordingly, rather than counting a number of sensing windows, LCP 100 may simply monitor signal 524 within any number of subsequent sensing windows which fall within the tracked period of time.

In other alternative embodiments, LCP 100 may track a moving average of the maximum amplitude of signal 524 over about three, about five, about ten, about fifteen, or about twenty cardiac cycles, or any other suitable number of cardiac cycles, and may store the determined moving averages in a memory. During a tamponade condition, this moving average will steadily decrease over time as the heart loses its ability to expand and pump blood due to blood pooling in the pericardial sac. Accordingly, in some embodiments, LCP 100 may compare the moving average to a threshold to determine whether a tamponade condition is occurring. In other or additional embodiments, LCP 100 may determine whether the stored moving averages decrease in a monotonic fashion. If LCP 100 determines that about five, about ten, about fifteen, or any other suitable number of consecutive determined moving averages decrease in a monotonic fashion, LCP 100 may determine that a tamponade condition is occurring.

Alternatively, LCP 100 may determine the slopes between consecutive determined moving averages. If LCP 100 determines that a threshold number, such as three, five, ten, fifteen, or twenty, of consecutive slopes are negative, LCP 100 may determine that a tamponade condition is occurring. Also, the magnitude of the slope(s) may be taken into consideration. A larger slope may indicate a more severe tamponade condition, and thus the LCP 100 may determine that a tamponade condition is occurring sooner.

Although the above tamponade detection techniques included monitoring for tamponade over a relatively short

time period, e.g. a number of cardiac cycles, in some additional or alternative embodiments, LCP 100 may be configured to monitor for a tamponade condition over longer periods of time. For instance, LCP 100 may be configured to monitor for tamponade once an hour, once every few hours, twice a day, or once a day. In these embodiments, LCP 100 may monitor, for example, the maximum amplitude of signal 524 during one or more sensing periods during each chosen time interval. LCP 100 may then compare the sensed maximum amplitude of signal 524 during each of these chosen time intervals to determine if there is a trend. For example, LCP 100 may compare these determined differences to one or more thresholds, as above, to determine if a tamponade condition is occurring. This may facilitate detection of slow-onset tamponade conditions.

FIG. 7 depicts another embodiment where LCP 100 may be configured to determine that a tamponade condition is occurring. FIG. 7 depicts a graph 540 showing an accelerometer signal 542, which may represent a magnitude of acceleration from an accelerometer of LCP 100. In the example of FIG. 7, LCP 100 may employ multiple thresholds in determining whether a tamponade condition is occurring. For example, LCP 100 may initially monitor accelerometer signal 542 during sensing windows 541a-541e to determine when a maximum amplitude of signal 542 within a sensing window falls below first threshold 543. Once LCP 100 determines that signal 542 has fallen below first threshold 543, LCP 100 may monitor accelerometer signal 542 to determine if, or when, accelerometer signal 542 falls below second threshold 545. In the example of FIG. 7, LCP 100 would determine that accelerometer signal 542 falls below second threshold 545 in the next sensing window 541d. At this point, after accelerometer signal 542 has fallen below the first threshold 543 and then subsequently fallen below the second threshold 545, LCP 100 may determine that a tamponade condition is occurring, as this trend may indicate declining mechanical motion of the heart. Of course, in additional embodiments, LCP 100 may only determine that a tamponade condition is occurring after determining that a maximum amplitude of accelerometer signal 542 in multiple subsequent sensing windows is still below second threshold 545, for instance in any manner that was described with respect to FIG. 6.

Of course, in some cases, the maximum amplitude of accelerometer signal 542 may be above both first threshold 543 and second threshold 545 in a first sensing window and may be less than both first threshold 543 and second threshold 545 in a next sensing window. In such embodiments, LCP 100 may monitor subsequent sensing windows and determine whether the maximum amplitude of accelerometer signal 542 stays below second threshold 545. If LCP 100 determines the maximum amplitude of accelerometer signal 542 stays below second threshold 545 for one or more subsequent sensing windows, LCP 100 may then determine that a tamponade condition is occurring. In such embodiments, the tamponade condition may worsen too quickly for LCP 100 to sense the decline in mechanical motion of the heart, and LCP 100 may instead rely simply on a consistent indication of low cardiac motion to determine that a tamponade condition is occurring.

In some embodiments, first threshold 543 may be set as a certain percentage of a maximum value of sensed signal 542 in a sensing window when signal 542 is sensed under conditions where it is known that tamponade is not occurring. For instance, first threshold 543 may be set at about seventy-five percent of the maximum value of sensed signal 542 in a sensing window. However, in other embodiments,

first threshold 543 may be set at different percentages of the maximum value of sensed signal 542 in a sensing window, such as about fifty percent, about sixty-percent, about seventy percent, about eighty percent, about eighty-five percent, about ninety percent, or any other suitable value. In some embodiments, the value of second threshold 543 may be programmable.

Second threshold 545 may be set at a certain percentage of first threshold 543. For instance, second threshold 545 may be set at about seventy-five percent of first threshold 543. However, in other embodiments, second threshold 545 may be set at different percentages of first threshold 543, such as about fifty percent, about sixty-percent, about seventy percent, about eighty percent, about eighty-five percent, about ninety percent, or any other suitable value. In some embodiments, the value of second threshold 545 may be programmable.

FIG. 8 depicts still another embodiment where LCP 100 may be configured to determine that a tamponade condition is occurring. FIG. 8 depicts a graph 550 showing an accelerometer signal 552, which may represent a magnitude of acceleration from an accelerometer of LCP 100. In the example of FIG. 8, LCP 100 may employ multiple thresholds in determining whether a tamponade condition is occurring. For example, LCP 100 may initially monitor accelerometer signal 552 during sensing windows 551a-551e to determine when a maximum amplitude of accelerometer signal 552 within a sensing window falls below first threshold 553.

Once LCP 100 determines that the maximum amplitude of signal 552 has fallen below first threshold 553, such as in sensing window 551c, LCP 100 may monitor accelerometer signal 552 to determine if, or when, accelerometer signal 552 rises above second threshold 555. For example, LCP 100 may monitor accelerometer signal 552 for a number of subsequent sensing windows, or for a predefined period of time, after detecting that the maximum amplitude of accelerometer signal 552 is less than first threshold 553. If LCP 100 determines that the maximum amplitude of accelerometer signal 552 did not rise above second threshold 555 within the predetermined number of subsequent sensing windows, or within the predefined period of time, LCP 100 may determine that a tamponade condition is occurring. If LCP 100 determines that accelerometer signal 552 did rise above second threshold 555 within the predetermined number of subsequent sensing windows, or within the predefined period of time, LCP 100 may then switch back to monitoring whether the maximum amplitude of accelerometer signal 552 is below first threshold 553.

In some embodiments, first threshold 553 may be set as a certain percentage of a maximum value of sensed signal 552 in a sensing window when signal 552 is sensed under conditions where it is known that tamponade is not occurring. For instance, first threshold 553 may be set at about seventy-five percent of the maximum value of sensed signal 552 in a sensing window. However, in other embodiments, first threshold 553 may be set at different percentages of the maximum value of sensed signal 552 in a sensing window, such as about fifty percent, about sixty-percent, about seventy percent, about eighty percent, about eighty-five percent, about ninety percent, or any other suitable value. In some embodiments, the value of second threshold 553 may be programmable.

Second threshold 555 may be set at a certain percentage of first threshold 553. For instance, second threshold 555 may be set at about seventy-five percent of first threshold 553. However, in other embodiments, second

threshold **545** may be set at different percentages of first threshold **543**, such as about fifty percent, about sixty-percent, about seventy percent, about eighty percent, about eighty-five percent, about ninety percent, or any other suitable value. In some embodiments, the value of second threshold **555** may be programmable.

FIG. 9 depicts still another embodiment where LCP **100** may be configured to determine that a tamponade condition is occurring. FIG. 9 depicts a graph **560** showing an accelerometer signal **562**, which may represent a magnitude of acceleration from an accelerometer of LCP **100**. In the example of FIG. 9, LCP **100** may employ multiple thresholds in determining whether a tamponade condition is occurring. For example, LCP **100** may initially monitor accelerometer signal **562** during sensing windows **561a-561e** to determine when a maximum amplitude of accelerometer signal **562** within a sensing window falls below first threshold **563**.

Once LCP **100** determines that the maximum amplitude of accelerometer signal **562** has fallen below first threshold **563**, such as in sensing window **561c**, LCP **100** may monitor accelerometer signal **562** to determine whether accelerometer signal **562** falls below second threshold **565** or rises above third threshold **567**. For example, LCP **100** may monitor accelerometer signal **562** for a number of subsequent sensing windows, or for a predefined period of time, after detecting that the maximum amplitude of accelerometer signal **562** is less than first threshold **563**. If LCP **100** determines that the maximum amplitude of accelerometer signal **562** rises above third threshold **567** before falling below second threshold **565**, LCP **100** may go back to determining whether the maximum amplitude of accelerometer signal **562** is below first threshold **563**. However, if LCP **100** determine that the maximum amplitude of accelerometer signal **562** does not rise above third threshold **567** within the predetermined number of subsequent sensing windows, or for the predefined period of time, LCP **100** may determine that a tamponade condition is occurring. Additionally, if LCP **100** determines that the maximum amplitude of accelerometer signal **562** falls below second threshold **565** at any point, LCP **100** may determine a tamponade condition is occurring, even if the predetermined number of subsequent sensing windows have not occurred, or the predefined period of time ran out.

In some embodiments, first threshold **563** may be set at a certain percentage of a maximum value of sensed signal **562** in a sensing window when signal **562** is sensed under conditions where it is known that tamponade is not occurring. For instance, first threshold **563** may be set at about seventy-five percent of the maximum value of sensed signal **562** in a sensing window. However, in other embodiments, first threshold **563** may be set at different percentages of the maximum value of sensed signal **562** in a sensing window, such as about fifty percent, about sixty-percent, about seventy percent, about eighty percent, about eighty-five percent, about ninety percent, or any other suitable value. In some embodiments, the value of second threshold **563** may be programmable.

Second threshold **565** and/or third threshold **567** may be set at a certain percentage of first threshold **563**. For instance, third threshold **567** may be set at about seventy-five percent of first threshold **563**. However, in other embodiments, third threshold **567** may be set at different percentages of first threshold **563**, such as about fifty percent, about sixty-percent, about seventy percent, about eighty percent, about eighty-five percent, about ninety percent, or any other suitable value. In some embodiments,

second threshold **565** may be set at about fifty percent of first threshold **563**. However, in other embodiments, second threshold **565** may be set at different percentages of first threshold **563**, such as about twenty-five percent, about thirty percent, about thirty-five percent, about forty percent, about forty-five percent, or any other suitable value. In some embodiments, the value of second and/or third threshold **565**, **567** may be programmable.

Although the embodiments of FIGS. 6-9 all use the magnitude of the accelerometer signal, it should be understood that this is for illustrative purposes only. In other embodiments, LCP **100** may use other signals to determine whether a tamponade condition is occurring. For example, LCP **100** may use any signal received from the accelerometer, such as the different signals representing different axes of the accelerometer, to determine whether a tamponade condition is occurring. LCP **100** may further process the accelerometer signal to derive one or more other signals for use in determining whether a tamponade condition is occurring. As one example, LCP **100** may double integrate the accelerometer signal to determine a displacement signal, representing the displacement of the accelerometer over time, which correlates to displacement of the heart wall. LCP **100** may compare a maximum amplitude of a portion of this displacement signal, such as during a filling of the heart, to one or more thresholds to determine whether a tamponade condition is occurring. For instance, the maximum amplitude of the displacement signal in the monitored portion may relate to the amount of movement of the cardiac wall during filling. As blood pools in the pericardial sac, the maximum value of this signal will decrease over time. Accordingly, LCP **100** may monitor whether this value decreases below one or more threshold and, if so, determine an occurrence of a tamponade condition. Like with the accelerometer signal, LCP **100** may use a feature of the cardiac electrical signal to determine which portion of the displacement signal to monitor. For instance, LCP **100** may track a period of time from a cardiac electrical event and begin monitoring the displacement signal for the maximum amplitude within a sensing window beginning upon expiration of the period of time. In at least some embodiments, the period of time used for the accelerometer signal and the period of time used for the displacement signal are different.

In still other embodiments, LCP **100** may include other sensors and may use signals from those sensors to determine whether a tamponade condition is occurring. Some other example sensors include a pressure sensor and/or a gyroscope. When provided, a gyroscope may be a multi-axis gyroscope and generate signals similar to the multi-axis accelerometer described above. In some cases, as mentioned previously, signals generated by a gyroscope may have a certain synchrony with the cardiac electrical signals which may change during a tamponade condition. Loss of the synchrony of a peak value of the gyroscope signal and the cardiac electrical events may indicate a tamponade condition is occurring. In other embodiments, LCP **100** may employ any of the techniques described with respect to the accelerometer signal to the gyroscope signal to determine whether a tamponade condition is occurring.

Further, as a tamponade condition is worsening, the intra-chamber blood pressure, and in particular the intra-chamber blood pressure as the heart contracts to pump the blood, may change over time in a diminishing manner. In these embodiments, LCP **100** may monitor an intra-chamber blood pressure signal detected via a pressure sensor and/or detected via heart sounds via an accelerometer or the like. For example, the amplitude of the first heart sound (**51**),

which can be detected by an accelerometer or the like, is proportional to the rate of left ventricular pressure rise (LV dP/dt). LCP 100 may compare a maximum amplitudes of this blood pressure signal taken over time to one or more thresholds. In general, any of the threshold techniques described above with respect to the maximum amplitude of the accelerometer may be applied to the blood pressure signal.

In some further embodiments, LCP 100 may monitor a time duration of the peak of the dP/dt signal, such as by monitoring how long the dP/dt signal stays within a certain percentage of the peak dP/dt signal value over a cardiac cycle, such as within about three percent, about five percent, about eight percent, or about ten percent. During a tamponade condition, this time value may lengthen. Accordingly, LCP 100 may compare this determined time value to a threshold, and LCP 100 may determine that a tamponade condition is occurring if the value rises above a threshold.

In still other embodiments, LCP 100 may monitor heart sounds for indications of valve closures, for instance based on deflections in the heart sounds signal. If LCP 100 determines that there is a lack of detected expected valve closures, LCP 100 may determine an occurrence of a tamponade condition. For instance, LCP 100 may expect to detect two, three, or four heart sound features in the heart sounds signal for each cardiac cycle. If LCP 100 detects less than is expected, LCP 100 may determine that a tamponade condition is occurring. Additionally, or alternatively, LCP 100 may determine that a tamponade condition is occurring if a monitored maximum amplitude of the heart sounds signal falls below a threshold for one or more cardiac cycles, or the heart sounds signal differs from a template heart sounds signal.

Accordingly, in any these above embodiments, instead of using signals from an accelerometer, LCP 100 may use signals from the gyroscope, the blood pressure sensors, or any other sensors in any manner described above to determine whether a tamponade condition is occurring.

In still other embodiments, LCP 100 may use multiple signals to determine whether tamponade is occurring. For instance, LCP 100 may perform analyses on multiple signals generated by the accelerometer, gyroscope, and/or blood pressure sensor. In some of these embodiments, LCP 100 may determine that a tamponade condition is occurring if analysis on any one signal indicates a tamponade condition. However, in other embodiments, LCP 100 may only determine that a tamponade condition is occurring if multiple of the signals indicate a tamponade condition, such as two signals, three signals, four signals, all of the signals, or any other suitable number of signals.

Where LCP 100 uses multiple signals to determine whether tamponade is occurring, LCP 100 may, in some examples, analyze the signals in a cascading fashion. For instance, LCP 100 may initially only monitor a single signal. After determining that the first signal indicates that a tamponade condition is occurring, LCP 100 may then begin to monitor a second signal. In some instances, only after the second signal has indicated that a tamponade condition is occurring does the LCP 100 determine that a tamponade condition is occurring. In some cases, LCP 100 may be able to cascade the analysis of the signals in order to save energy. For instance, in some embodiments LCP 100 may be configured to monitor a first signal from an accelerometer while the other channels of the accelerometer or other sensors are turned off. Only after the first accelerometer signal indicates that a tamponade condition is occurring does the LCP 100 turn on another channel of the accelerometer or other

sensor(s) in order to analyze a second signal. In different embodiments, LCP 100 may use any of the above described signal(s) in any cascading combination in order to determine whether a tamponade condition is occurring.

Additionally, although the techniques of the present disclosure were described in relation to a maximum amplitude of the signal from the accelerometer or other sensor, in other embodiments, LCP 100 may use different characteristics of the signals. As one example, the value of the integral, or double integral, of the analyzed signal within the sensed window may be used instead of the maximum amplitude of the signal. In these embodiments, the value of the integral or double integral may be compared to one or more thresholds, in a similar manner to that described with respect to the maximum amplitude of the signal, to determine whether a tamponade condition is occurring. In another example, a peak width of a signal may be used. For example, as detailed, above, how long a dP/dt signal stays within a certain percentage of the peak dP/dt signal value may be used to determine if a tamponade condition is occurring.

After determining that a tamponade condition is occurring, LCP 100 may generate an alarm signal or message and communicate the alarm signal to a device external to LCP 100. For instance, where LCP 100 is part of a medical device system, such as system 400, LCP 100 may communicate the alarm signal to external support device 420. External support device 420 may then generate a visual or audible alarm to notify a user in the vicinity of external support device 420 that LCP 100 has determined that a tamponade condition is occurring. In other embodiments, LCP 100 may communicate the alarm signal to another internally implanted device, for instance pulse generator 406, and the other internally implanted device may communicate the alarm signal to a device outside of the patient. In some embodiments, LCP 100, or another device which receives the alarm signal from LCP 100, may be connected to one or more wireless networks. LCP 100, or another device of the system, may connect to the wireless network to communicate the alarm signal to a remote device, such as a pager, cell phone, or other remote device connected to the wireless network.

Additionally, although the above described techniques are centered around LCP 100 performing the sensing and determining functions, where LCP 100 is part of a device system, such as system 400 of FIG. 4, other devices of the system may perform at least some of these functions. For example, LCP 100 may monitor or sense signals from an accelerometer or pressure sensor of the LCP 100 and communicate those signals, or portions of those signals, to another device, such as pulse generator 406. Pulse generator 406 may then determine whether a tamponade condition is occurring. If pulse generator 406 determines that a tamponade condition is occurring, pulse generator 406 may then communicate an indication that a tamponade condition is occurring, for instance as described with respect to LCP 100. In other embodiments, the device doing the determining, based on signals received from LCP 100, may be external support device 406.

Those skilled in the art will recognize that the present disclosure may be manifested in a variety of forms other than the specific embodiments described and contemplated herein. For instance, as described herein, various embodiments include one or more modules described as performing various functions. However, other embodiments may include additional modules that split the described functions up over more modules than that described herein. Additionally, other embodiments may consolidate the described functions into fewer modules.

Although various features may have been described with respect to less than all embodiments, this disclosure contemplates that those features may be included on any embodiment. Further, although the embodiments described herein may have omitted some combinations of the various described features, this disclosure contemplates embodiments that include any combination of each described feature. Accordingly, departure in form and detail may be made without departing from the scope and spirit of the present disclosure as described in the appended claims.

What is claimed is:

1. A method for detecting a tamponade condition of a patient's heart after attachment of a leadless cardiac pacemaker to the patient's heart, the leadless cardiac pacemaker having an accelerometer that produces an accelerometer signal, the method comprising:

monitoring the accelerometer signal of the leadless cardiac pacemaker;

determining if a tamponade condition of the patient's heart is indicated based at least in part on the monitored accelerometer signal, including:

identifying a characteristic of the accelerometer signal; determining if the identified characteristic diminishes over time; and

determining that the tamponade condition is indicated if the identified characteristics of the accelerometer signal diminishes over time; and

in response to determining that the tamponade condition is indicated, providing a notification of the tamponade condition for use by a physician to take corrective action.

2. The method of claim 1, wherein the identified characteristic comprises a peak amplitude of the accelerometer signal.

3. The method of claim 1 wherein the identified characteristic comprises a peak amplitude of an integral of the accelerometer signal.

4. The method of claim 1, wherein the accelerometer signal represents one axis of a multi-axis accelerometer.

5. The method of claim 1, wherein the accelerometer signal represents a summed signal of all axes of a multi-axis accelerometer.

6. The method of claim 1, wherein determining if the identified characteristic diminishes over time comprises determining if the identified characteristic falls below a predetermined threshold.

7. The method of claim 1, wherein the leadless cardiac pacemaker performs the monitoring, determining and providing steps.

8. The method of claim 1, wherein the leadless cardiac pacemaker performs the monitoring step.

9. The method of claim 1, wherein an external device programmer performs one or more of the monitoring, determining and providing steps.

10. The method of claim 1, wherein providing the notification comprises communicating a message from the leadless cardiac pacemaker for reception by an external device programmer.

11. A leadless cardiac pacemaker for use in pacing a patient's heart, comprising:

a plurality of electrodes;

an accelerometer for providing an accelerometer signal;

a controller operatively coupled to the plurality of electrodes and the accelerometer, the controller configured to:

monitor the accelerometer signal of the accelerometer over time;

determine if a tamponade condition of the patient's heart is indicated based at least in part on the monitored accelerometer signal, including:

identifying a characteristic of the accelerometer signal;

determining if the identified characteristic diminishes over time; and

determining that the tamponade condition is indicated if the identified characteristic of the accelerometer signal diminishes over time; and

in response to determining that the tamponade condition is indicated, communicate a notification of the tamponade condition for use by a physician to take corrective action.

12. The leadless cardiac pacemaker of claim 11, wherein the notification of the tamponade condition is communicated using two or more of the plurality of electrodes of the leadless cardiac pacemaker.

13. The leadless cardiac pacemaker of claim 11, wherein the identified characteristic comprises a peak amplitude of the accelerometer signal.

14. The leadless cardiac pacemaker of claim 11, wherein the identified characteristic comprises a peak amplitude of an integral of the accelerometer signal.

15. A leadless cardiac pacemaker, comprising:

a plurality of electrodes;

an accelerometer for providing an accelerometer signal; a controller operatively coupled to the plurality of electrodes and the accelerometer, the controller configured to:

monitor an indication of a range of physical motion of a patient's heart over time using the accelerometer signal;

determine if the indication of the range of physical motion of the patient's heart reduces over time by at least a predefined amount; and

if it is determined that the indication of the range of physical motion of the patient's heart has reduced over time by at least the predefined amount, communicate a notification of a possible tamponade condition for reception by a remote device that is remote from the leadless cardiac pacemaker.

16. The leadless cardiac pacemaker of claim 15, wherein the controller is further configured to monitor a heart rate of the patient's heart over time and to determine if the heart rate increases over time by at least a predetermined heart rate amount.

17. The leadless cardiac pacemaker of claim 16, wherein the controller only communicates a notification of the possible tamponade condition if it is determined that the indication of the range of physical motion of the patient's heart has reduced over time by at least the predefined amount and the heart rate of the patient's heart has increased over time by at least the predetermined heart rate amount.

18. The leadless cardiac pacemaker of claim 15, wherein the notification of the possible tamponade condition is communicated using two or more of the plurality of electrodes of the leadless cardiac pacemaker.

专利名称(译)	用于检测堵塞的系统和方法		
公开(公告)号	US10159842	公开(公告)日	2018-12-25
申请号	US15/244571	申请日	2016-08-23
[标]申请(专利权)人(译)	心脏起搏器股份公司		
申请(专利权)人(译)	心脏起搏器, INC.		
当前申请(专利权)人(译)	心脏起搏器, INC.		
[标]发明人	KANE MICHAEL J SHUROS ALLAN CHARLES SCHMIDT BRIAN L MAILE KEITH R HAASL BENJAMIN J		
发明人	KANE, MICHAEL J. SHUROS, ALLAN CHARLES SCHMIDT, BRIAN L. MAILE, KEITH R. HAASL, BENJAMIN J.		
IPC分类号	A61N1/37 A61B5/00 A61N1/05 A61N1/375 A61B5/024 A61B5/02 A61B5/029 A61B5/11		
CPC分类号	A61N1/3704 A61B5/0031 A61B5/024 A61B5/029 A61B5/11 A61B5/6869 A61N1/057 A61N1/3756 A61B5/02028 A61B2562/0219		
审查员(译)	LEE, ERICA		
优先权	62/211333 2015-08-28 US		
其他公开文献	US20170056671A1		
外部链接	Espacenet		

摘要(译)

公开了用于确定堵塞条件的发生的系统, 方法和设备。一种示例性方法包括监测附接到心脏壁的无引线心脏起搏器的加速度计信号, 确定是否至少部分地基于所监测的加速度计信号指示患者心脏的堵塞状况, 并且响应于确定堵塞状况指示, 提供堵塞条件的通知以供医生用于采取纠正措施。

